Clemson University

TigerPrints
All Dissertations

Dissertations

8-2007

Functional Genomics of the Angiotensin II Type 2
Receptor in the Developing Brain
Traci Pawlowski
Clemson University, tpawlow@clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Part of the Genetics Commons
Recommended Citation
Pawlowski, Traci, "Functional Genomics of the Angiotensin II Type 2 Receptor in the Developing Brain" (2007). All Dissertations. 111.
https://tigerprints.clemson.edu/all_dissertations/111

This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

FUNCTIONAL GENOMICS OF THE ANGIOTENSIN II TYPE TWO
RECEPTOR IN THE DEVELOPING BRAIN
A Dissertation
Presented to
the Graduate School of
Clemson University
In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Genetics
by
Traci Bryant-Pawlowski
August 2007
Accepted by:
Anand K. Srivastava PhD, Committee Chair
Albert Abbott PhD
Chin-Fu Chen PhD
Barbara Dupont PhD
James Morris PhD

ABSTRACT
The mammalian brain expresses two angiotensin II specific receptors, the
angiotensin II type 1 (AGTR1) and type 2 (AGTR2). Studies in humans and mice
indicate a possible role for AGTR2 in learning, memory and behavior. However,
AGTR2 gene function in the brain, and the molecular mechanisms by which
AGTR2 exerts its physiological action, remains elusive. This study examines the
possible role of AGTR2 in the developing brain and in brain function by employing
three different approaches.
To identify genes in the developing brain that depend on AGTR2 function,
a microarray analysis was conducted that compared the gene expression of Agtr2-/y
mouse brains to normal controls at embryonic day 15 and postnatal day 1. Genes
involved in microtubule regulation, cell adhesion and glutamate metabolism were
found to be up-regulated in Agtr2-/y mouse brains. These results suggest that AGTR2
may contribute to the developing brain by influencing cell morphology and synaptic
connectivity.
Using a yeast two-hybrid system, the amino-terminal extracellular domain
and carboxy-terminal intracellular domain of AGTR2 were screened against a human
fetal brain cDNA library to identify AGTR2 interacting proteins. Three novel
AGTR2 interacting proteins, ASMTL, GNB2L1 and NGLY1 were identified.
Lastly, a brain-specific isoform of a previously identified AGTR2 interacting
protein, ATIP, was explored as a potential candidate gene for mental retardation.
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Limited screening of the ATIP gene in 80 patients with mental retardation identified
two non-pathogenic sequence variants but no disease causing mutations.
In summary, this study unveils several functional classes of genes as potential
downstream targets of AGTR2 and identifies three new AGTR2 interacting proteins
in the developing brain. Further functional studies of the newly identified AGTR2
interacting proteins and some of the genes influenced by AGTR2 may provide clues
to AGTR2-mediated signaling in the developing brain and in brain function.
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PREFACE
Mental retardation (MR), defined by an IQ score less than 70, affects
approximately 1-3% of the human population (Chelly and Mandel 2001). The causes
of MR are many, and in up to 40% of cases the cause is unknown (Chelly and
Mandel 2001). When the cause is known, mental retardation can result from prenatal
insults, environmental factors, injuries and genetic causes. The genetic component
of MR likely includes mutations in a large number of genes distributed throughout
the genome. X-linked mental retardation is the most common cause of MR in males
(Stevenson 2005).
The role of angiotensin II (Ang II) in the renin-angiotensin system (RAS) has
been well characterized as an enzyme-neuropeptide system in the brain, as well as for
its role in blood pressure control and fluid homeostasis. The action of the Ang II
peptide is primarily mediated by its two receptors, Angiotensin II type 1 receptor
(AGTR1) and Angiotensin II type 2 receptor (AGTR2). The RAS has been shown
to regulate sensory information, learning and emotional response (von Bohlen und
Halbach and Albrecht 2006). Several components of the RAS have been implicated
as having roles in brain development and function. Mutations in the AGTR2 gene
have been found in individuals with MR (Vervoort et al. 2002; Ylisaukko-ojo et al.
2004), and a family with X-linked MR and epilepsy has been found to have a
mutation in the renin receptor (Ramser et al. 2005).
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All components of the RAS are present in several areas of the body including
the kidney, blood vessel walls, heart and brain (Lavoie and Sigmund 2003). In the
classic RAS, angiotensinogen is converted to angiotensin I by renin. Angiotensin I
is cleaved by angiotensin converting enzyme (ACE) to make angiotensin II (Figure
P.1). Angiotensinogen can also be cleaved by cathespin D or tonin to make
angiotensin II. Cathespin G, chymostatin-sensitive angiotensin II generating
enzyme (CAGE), and chymase can also cleave angiotensin I to make angiotensin II
(Lavoie and Sigmund 2003; von Bohlen und Halbach and Albrecht 2006). Ang II is
likely the first neuroactive form of the angiotensins. Other neuroactive angiotensins
include angiotensin IV and angiotensin (1-7) and are produced by the actions of
other enzymes (von Bohlen und Halbach and Albrecht 2006).
Physiologically AGTR2 has been shown to balance the actions of AGTR1
(Hein et al. 1995; Ichiki et al. 1995; AbdAlla et al. 2001). AGTR2 has been shown
to inhibit AGTR1 actions by directly binding to AGTR1 (AbdAlla et al. 2001). The
role of AGTR1 is very well characterized, but the functions of AGTR2 remain
elusive. The purpose of this study is to elucidate the physiological function of
AGTR2 in the developing brain.
The RAS mediates the expression of AGTR1 and AGTR2 by the level of
angiotensin II produced, and thus the signaling cascades controlled by each
respective receptor. Stimulation of AGTR1 raises blood pressure, increases cellular
Ca2+ , depolarizes sodium channels and contributes to cell proliferation (Allen et al.

3

1998; Berry et al. 2001). Conversely, activation of AGTR2 lowers blood pressure,
hyper-polarizes sodium channels and induces apoptosis (Berry et al. 2001). Different
signaling cascades are mediated by angiotensin II depending on whether it is bound
by AGTR2 or AGTR1. Binding of angiotensin II to AGTR1 causes endocytosis of
AGTR1 but not AGTR2 (Hein et al. 1997). AGTR1 induces phosphorylation by
tyrosine kinase and up-regulates Map kinases (MAPK), which up-regulates
transcription of various genes affecting cell proliferation (Berry et al. 2001). AGTR1
also induces vasoconstriction via the phosphatidyl inositol pathway (Berry et al.
2001). Conversely, AGTR2 through the activation of protein phosphatase 2A
(PP2A), inhibits MAPK expression.

Through stimulating ERK phosphatase,

AGTR2 also promotes apoptosis as well as vasodilation through nitrous oxide
synthetase and phospholipase A2 (Berry et al. 2001). AGTR2 has also been shown
to regulate cell growth (Goto et al. 1997). These functions are summarized in Figure
P.1.
Functional studies of AGTR2 in neuronal cells suggest it has a role in
apoptosis and cell differentiation. AGTR2 has been found to mediate apoptosis in
PC12W and R3T3 cells (Yamada et al. 1996) AGTR2 has been localized to neurons
but not glial cells and has been shown to influence morphology of several cell types
including NG-108-15, PC12W and rat neuronal cell lines (Gendron et al. 2003). Its
effects on neuronal growth and differentiation are complex. In PC12W cells,
AGTR2 was found to up-regulate MAP2, polymerize beta-tubulin levels and down-
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regulate MAP1B protein levels. MAP2 has been associated with elongation of axons
(Shea and Flanagan 2001). Thus a possible role for AGTR2 in nerve regeneration
and cell differentiation was suggested (Stroth et al. 1998).

Figure P.1 The angiotensin II receptors signaling cascade. The physiological
functions affecting the developing brain are highlighted in orange.
Using NG-108-15 cells, Gendron and associates (1999) found that AGTR2
stimulates neurite outgrowth via an increase in MAPK activity and a decrease in
p21ras activity in a time dependent manner. The inhibition of protein kinase C
(PKC) by AGTR2 has also been shown to inhibit cell proliferation by PKC
inhibiting p21ras and then up-regulating Rap1 and the p42/p44mapk pathway to allow
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neurite elongation (Beaudry et al. 2006). AGTR2 has also been shown to stimulate
neuronal differentiation by its association with MMS2 and a complex of ATIP and
SHP-1 in rat neuronal cells (Li et al. 2007).
Both receptors are expressed in the hippocampus, the cingulate cortex, parts
of the amygdala, the anterior thalamus, the paraventricular nucleus, the supraoptic
nucleus, the superior and inferior colliculi, the locus coeruleus, the inferior olive
and the vagal nucleus (reviewed in von Bohlen und Halbach and Albrecht 2006).
AGTR2 is uniquely expressed in the lateral septal area, habenula, centromedial
thalamus, medial geniculate nucleus, reticular nucleus, ventral segmental area,
hypoglossal nucleus, motor trigeminal nucleus and the cerebellum (von Bohlen und
Halbach and Albrecht 2006).
In the mouse fetus, expression of AGTR2 has been shown to be relatively
higher and more diverse in the developing brain than in adulthood (Johren and
Saavedra 1996; Nuyt et al. 1999; Saavedra 2005). Using a cRNA probe, Nuyt and
co-workers (1999) found AGTR2 in the developing rat brain beginning at E11 in the
lateral hypothalamic area and then increasing in expression and location throughout
gestation and 28 days postnatally.
A female patient with mental retardation and absence AGTR2 gene expression
was described previously (Vervoort et al. 2002). A subsequent screening of 590
unrelated patients with MR revealed one frame shift and three missense mutations in
eight patients (Vervoort et al. 2002). In a separate screening of 360 unrelated males
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with non-syndromic X-linked mental retardation, one patient was found to have a
p.C117F change in the N-terminal domain of AGTR2 which was determined to be a
rare polymorphic variant (Bienvenu et al. 2003). A study of 57 similarly affected
Finnish male patients found one patient with the G21V mutation and one with an
I53F in the transmembrane domain (Ylisaukko-ojo et al. 2004).

However, Erdman

and co-workers (2004) found in a screening of 631 males and 277 females, that 1
male with dilated cardiomyopathy and another male with hypertrophic
cardiomyopathy had the G21V mutation as well as 2 normal controls. None of these
patients had reported mental deficits. Several proteins (Erb3, PLZF, ATIP, NHE6)
have been found to interact with AGTR2 through in-vivo and in-vitro studies
(Knowle et al. 2000; Senbonmatsu et al. 2003; Nouet et al. 2004; Pulakat et al. 2005).
The sequence changes detected in patients with MR and the location known AGTR2
interacting proteins are indicated in Figure P.2.
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Figure P.2 Summary of mutations and interactions of AGTR2. Mutations are in
red, blue boxes are interacting proteins. ECD=extra-cellular domain, ECL = Extracellular loop, TMD = transmembrane domain, ICL = intracellular loop, ICD =
intracellular domain.
The AGTR2 gene is located at chromosome Xq23 in humans. The gene is 4250
bp long, consisting of 3 exons. The entire open reading frame is contained in exon 3
and transcribes a 2882 bp transcript. The AGTR2 protein is a seven transmembrane
receptor consisting of 363 amino acids of 41.2 kDa (Koike et al. 1994). AGTR2 is
highly expressed in fetal tissues with expression reducing rapidly after birth and then
predominately only being expressed in the cerebellum, kidney, heart, adrenals,
vasculature and pancreas (Berry et al. 2001).
In the mouse, the Agtr2 gene is located on XA1.3. The gene is 4539 bp long,
consisting of 4 exons making a 3204 bp transcript. The coding region has been
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found in exons 3 and 4, and encodes a 363 amino acid protein with a 95% homology
to the human receptor (Eppig and Bult 2005).
The first AGTR2 knock-out mouse models were described in 1995 (Hein et
al. 1995; Ichiki et al. 1995). These mice were viable and fertile. The mutant males
showed increased fear and a reduction in exploratory behavior and decreased body
temperature, sensitivity to pain, startle response and drinking response. Cell number
in the brains of the Agtr2-/y mice was increased, but cell size was not affected (von
Bohlen und Halbach et al. 2001) Sakagawa and collaborators (2000) found that
AGTR2 knockout mice had an increased sensitivity to pain and lower levels of brain
β-endorphin.
Microarrays are used in Chapter 1 to elucidate the differences in gene
expression in the brains of Agtr2-/y versus normal embryonic day 15 (E15) and
postnatal day one (P1) mice. Our findings point to predicted and novel pathways for
AGTR2 in brain development, as well as differences in its function at different
points in development.
In Chapter 2, the screening of a human fetal brain library with the N-terminal
and C-terminal domains of AGTR2 utilizing a yeast two-hybrid system is discussed.
The screening with the N-terminal domain found three novel interacting proteins:
GNB2L1, (also known as RACK-1), NGLY1 and ASTML.
In Chapter 3, angiotensin II interacting protein (ATIP) is partially
characterized. ATIP has previously been shown to interact with the C-terminal
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intracellular domain of AGTR2 (Nouet et al. 2004; Wruck et al. 2005). One isoform
of the ATIP gene is characterized in the central nervous system. A mutation screen
of ATIP in patients with MR was undertaken, but no disease causing mutations were
identified.
A female patient with an X;7 translocation and an absence of AGTR2 gene
expression (Vervoort et al. 2002), is discussed in the appendix. This patient did not
have a disrupted AGTR2 gene, so several molecular methods were employed to
attempt to find a regulatory region for AGTR2. A deletion in the patient’s Xq22
chromosome region was found. This region contained a pseudogene for SUMO2
was found, which may contribute to the absent expression of AGTR2. Though the
patient’s CUTL1 gene was disrupted on chromosome 7, the patient demonstrated
expression of this gene.
In summary, work in this dissertation includes identification of genes whose
functions are likely influenced by AGTR2 in the developing brain. Three proteins
that interact with AGTR2 were identified and partially characterized in patients with
AGTR2 defects. A previously identified AGTR2 interacting protein, ATIP, was
characterized and tested as a candidate gene for mental retardation. Altogether, the
results support a likely role of AGTR2 mediated signaling in brain development and
function.
.
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MICROARRAY ANALYSIS REVEALS GENES CONTRIBUTING TO
ABNORMAL DENDRITIC SPINES IN AGTR2-/Y MOUSE
Mental retardation (MR) is the most common developmental disability,
affecting cognitive function in about 1-3% of the human population. Studies in
humans and mice indicated a possible role for the angiotensin II type 2 receptor
(AGTR2) in learning, memory and behavior. However, AGTR2 gene function in
the brain and the molecular mechanism by which AGTR2 exerts is physiological
action remains elusive.
The role of the renin-angiotensin system in blood pressure control and fluid
homeostasis is well established. Angiotensin II binds to angiotensin II type one
receptor (AGTR1) and type 2 receptor (AGTR2) receptor. Both receptors have
been shown to have opposing physiological effects (Berry et al. 2001). AGTR1
affects vasoconstriction, cell proliferation, cell hypertrophy, superoxide production,
endothelin release, lipid peroxidation, adhesion molecule expression and vascular
matrix expression primarily through phospholipases C, D and A2 (Berry et al., 2001;
(Csikos et al. 1998). The AGTR2 receptor has been shown to have a balancing effect
to AGTR1 in regard to blood pressure and natriuresis (Berry et al. 2001). It has also
been shown to inhibit growth and induce apoptosis (Yamada et al. 1996). It also
decreases cyclic guanosine monophosphate levels (GMP) and increases the
production of arachidonic acid (Nahmias and Strosberg 1995). AGTR2 activates
serine/threonine protein phosphatase two A (PP2A), the nitric oxide pathway as
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well as phospholipase A2 which contribute to vasodilation through the upregulation
of prostaglandins, bradykinin and nitric oxide (Berry et al. 2001). The synthesis of
ceramide also has been associated with stimulation of AGTR2 which in turn induces
apoptosis (Lehtonen et al. 1999; Berry et al. 2001).
AGTR2 has also been shown to up-regulate the microtubule proteins
polymerized β-tubulin and MAP2 in PC12W cells (Stroth et al. 1998).

It has also

been demonstrated that stimulation of AGTR2 inhibits cell proliferation and induces
neurite outgrowth (Meffert et al. 1996). AGTR2 knockout mice showed an
increase in cell number in the brain, especially in the ventral thalamic nuclei and
medial nucleus of the amygdala that persists into adulthood (von Bohlen und
Halbach et al. 2001).
Previous findings have shown that AGTR2 knockout mice were viable and
fertile (Hein et al. 1995; Ichiki et al. 1995). However, the behavior and learning
abilities of AGTR2 knockout mice differ from normal mice. AGTR2 knockout mice
demonstrate a lowered pain threshold than normal mice (Sakagawa et al. 2000).
These mice also show more anxiety type behaviors (Okuyama et al. 1999). Mutant
mice lacking the Agtr2 gene (Agtr2-/y ) were found to be significantly impaired in their
learning performance and exhibited abnormal dendritic spine morphology (C. Maul,
unpublished data), a feature consistently found to be associated with MR. In a test
of spatial memory, six month old AGTR2 knockout mice exhibited impaired
performance in a maze and also demonstrated impaired learning in a one-way active
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avoidance task (Maul unpublished data). These mice also have a decrease in
spontaneous movement (Hein et al. 1995) and exploratory behavior (Ichiki et al.
1995).
Expression of AGTR2 has been shown to be ubiquitous in the fetus and
then declines rapidly after birth (Grady et al. 1991). Expression in the rat brain is
detectable at embryonic day 13 (E13) and its expression changes in both intensity
and locality in the brain throughout prenatal development and postnatally (Nuyt et
al. 1999).
In order to identify transcripts in the developing brain that depend on
AGTR2 function, we analyzed RNA isolated from brains of Agtr2-/y and control mice
at developmental stage E15 and at birth using Agilent Whole Mouse Genome 44K
arrays. Gene expression profiles of the Agtr2-/y brain samples were compared to
profiles of the control brains. Furthermore, the expression profiling data generated
in this study point to a role for AGTR2 that is likely independent of the reninangiotensin system.
Methods
Animals
Pre-dissected organs from animals were provided from Agtr2-/y breeding
stocks by Dr. T. Walther at the Charité, Campus Benjamin Franklin, Berlin,
Germany. These mice are from the 129/sv strain on a C57BL/6 x 129 mixed
genetic background with a disrupted Agtr2 gene.
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Genotyping of animals was performed after isolating DNA from liver. PCR
was performed with the following primer sets: knockout- NeoPvu-F – 5’
GGCAGCGCGGCTATCGTGG 3’ and control – AT25 (F) 5’ CCACCAGCAGAAACATTACC 3’ and the same reverse primer was used for both: AT23 (R) 5’ GAACTACATAAGATGCTTGCCAGG 3’. (Primer sequences provided by T. Walther)
The following conditions were used for amplification: 95ºC for 5 min., 95ºC for 30
sec., 60ºC for 30 sec., 72ºC for 45 sec. for 30 cycles followed by 72ºC for 7 min. Sex
was determined by genotyping with an X-linked gene Jarid1 C, using the following
primers: Forward 5’ CTGAAGCTTTTGGCTTTGAG 3’ and reverse – 5’
CCACTGCC-AAATTCTTTGG 3’ with the following conditions: 95ºC for 5 min.,
95ºC for 20 sec., 56ºC for 30 sec., 72ºC for 40 sec. for 30 cycles followed by 72ºC for
7 min. (Clapcote and Roder 2005) Jarid1 C primers will produce a 331 bp and 302
bp band in males and a single 331 bp band in females, as there is a homologue to
Jarid1 C on the Y chromosome (Figure 1.1).
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Figure 1.1 Agarose gel of Jarid1C PCR of E15 Agtr2-/y mouse DNA. Males have a
331 bp and 302 bp band and females have a 331bp band. Control female is indicated
by the arrow.
RNA extraction
Total RNA was extracted from frozen slices of whole brain weighing less
than 30µg using the Qiagen RNeasy kit (Qiagen) according to manufacturer
instructions. Samples were cleaned with DNase using the Ambion Turbo DNasefree kit (Ambion Inc.). RNA samples were analyzed on the Agilent 2100 expert
bioanalyzer (Agilent) for purity and concentration. Two microliters of purified
RNA were loaded on a RNA 6000 Nano LabChip (Agilent) along with 2 µl of RNA
ladder (Ambion) and fluorescent marker from the Nano LabChip kit. The chip was
read by the Agilent 2100 Bioanalyzer. The bioanalyzer software computed sample
concentration, ratio of 18S to 28S ribosomal RNA and produced a gel image and
electropherogram.
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Microarray hybridization
RNA from 6 male controls and 8 male knockouts at stage E15 was amplified
individually and labeled with the Agilent low RNA Input Linear Amplification Kit
(Agilent) according to manufacturer instructions. In brief, cDNA was synthesized
using a T7 primer and was then labeled with Cy3- or Cy5-CTP. Samples were
purified with Qiagen RNasey mini spin columns (Qiagen). Equal amounts of
control sample and Agtr2-/y sample were labeled with Cy3 or Cy5 respectively and
were hybridized to the first set of 8 Agilent Whole Mouse Genome Oligo 44K
Microarrays slides (Agilent) according to the Agilent protocol. On the second set of
microarray slides, the control samples were paired with a different knockout sample.
The experimental strategy is outlined in figure 1.2. Arrays were hybridized for 17
hours at 65ºC and then washed with 6X SSC, 0.005% Triton X-102 for one minute
and then with 0.1X SSC, 0.005% Triton X-102 for one minute and then for 30
seconds in ozone scavenging solution (Agilent #5185-5979) . The microarray slides
were scanned on an Agilent microarray scanner and data was normalized and
extracted with Feature Extraction 8.0 software (Agilent). RNA from 4 male control
and 4 P1 Agtr2 -/y brains was handled in the same fashion, with all controls being
dye-swapped with a different knockout in each dye selection (Figure 1.2).
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Figure 1.2 Experimental design for E15 and P1 mouse brains on Agilent Whole
Mouse Genome 44K expression arrays demonstrating dye-swap strategy. K =
Agtr2-/y samples, C = control samples.
Data analysis
Normalized data from each array were reviewed to determine hybridization
efficiency. Two arrays were not included due to poor hybridization. A list of over
and under expressed genes for each developmental stage was generated using a
Student’s t-test with a Benjamini and Hochberg false discovery rate (Benjamini 2000)
statistic using both GeneSpring GX (Agilent) and Bioconductor marray and limma
software (Smyth 2005; Team 2005; Yee 2005). A list was produced using
GeneSpring GX© using a p≤ 0.001 and a FDR ≤ 0.3 for stage E15 of 88 up-
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regulated and 45 down-regulated genes. Ninety-five genes had on-chip replicates
and 5,996 genes had insufficient data for a comparison. Also using GeneSpring GX
with a p ≤ .005 and a FDR ≤ .3, for the newborn stage, a list of 270 up-regulated
and 127 down-regulated genes was produced. There were 2971 genes that had
insufficient data for comparison. Using the R statistical language (Team 2005)
Bioconductor with the marray (Yee 2005) and limma (Smyth 2005) packages were
implemented to provide a second analysis. The p-values with a Benjamini and
Hochberg false discovery rate and the fold change using a log2 transformation of all
genes on all arrays were calculated using limma. A summary of the creation of the
final lists is seen in Figures 1.3a and 1.3b. Annotation of genes in the list were
enhanced buy using the DAVID Gene Id Conversion Tool (Dennis et al. 2003).
Hierarchical clustering (condition tree) of the embryo arrays was performed
by GeneSpring GX using a Pearson correlation with a clustering algorithm = average
linkage, with a separation ratio of 1 and a minimum distance of 0.001 using the E15
final list. Clustering of the P1 arrays (gene tree) was performed in the same way
using a Pearson correlation with a clustering algorithm = average linkage, discarding
genes with no data in half the starting conditions and bootstrapping 100 sets. Gene
tree clustering on the entire embryo set was not possible due to computing
limitations.
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Figure 1.3a Flow chart of creation of E15 final list. Normalized data was analyzed
with GeneSpring GX and Bioconductor Limma to add strength to the results.

Figure 1.3b Flow chart of creation of P1 final list. Normalized data was analyzed
with GeneSpring GX and Bioconductor Limma to add strength to the results.
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Quantitative PCR
RNA was isolated as previously described on 4 controls and 4 knockouts
from each developmental stage, and from mice other than ones used in the
microarray experiment previously. Primers were designed using the Primer3
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen and
Skaletsky 2000). Biorad I-Script 1 step RT-PCR with SYBR green (Biorad) was used
according to manufacturer instructions with 5 ng of RNA per sample used. Samples
were run in triplicate on a Biorad i-cycler and analyzed using a standard curve
method (Larionov et al. 2005)A control gene, AK029535 (Riken cDNA493050c13)
was selected from a list of genes showing the least difference in expression generated
by limma using the model 1a algorithm as described by Szabo et. al (Szabo et al.
2004). The list of primers used is in Table1.1.
Table 1.1
Primers for Quantitative RT-PCR of E15 and P1 Mouse Brains
Primer
Name

Genebank
Accession

Annealing
Temperature
ºC

AK029535

AK029535

55

Prdm16

NM_027504

63

Bmp2kb

NM_080708

60

Pisd

AK005333

61

013803

AK013803

53

Sequence 5’ – 3’
F-GACAGTGGAGGGGAGAATGA
R -ACCGAGTTCTGGGTGTTGAC
F-AGGGCAAGAACCATTACACG
R-AGAGGTGGTCGTGGGTACAG
F-CATTTCCGATTCCAAGGAGA
R-GGAAGGACCCGTGTACTGAA
F-GGAGCAGTGACCACACTGAA
R-ACATCTTGCGTAGGCACAGG
F-TGGCTCTCTTCCTGATTGGT
R-CCAAACAAGGGTCTTCCAAA

Product
Size
(bp)
240
247
224
150
190
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Table 1.1 (continued)
Prosc

BC047992

64

C77370

XM_205178

57

050558

AK050558

64

Syn2

NM_013681

57

Mtap2

AK086484

55

NM_177054

55

Prie4

AK009137

56

Ube2m

NM_145578

61

Gnb2l1

NM_008143

55

Achy

L32836

50

Gls

AK047664

65

Rbm26

NM_134077

55

Add1

AK031960

62

S3fb

AK017529

62

Chuk

NM_007700

61

Gpi

AK051363

56

Atp6

AF093677

55

Pp2cb

NM_017374

53

Frg1

NM_013522

60

Nasp

NM_016777

60

At2b

NM_007429

55

Ace

NM_207624

61

Agtr1a

NM_177322

57

Casc4

F-AGGGTGTGGTGAGGATTCTG
R-GACGAGAACTGTGCACCTGA
F-GCAGGACTTGCTTAGGTTGC
R-TTGACTTATGCAGGGGGAAG
F-TCTTTCCCGAGTTCTGCTGT
R-GGGAACAACCAGGCTCATAA
F-ATGGCAAAGATGGCAAAGAC
R-CCGGTTCCTTAAGTGTTCCA
F-CTGGACATCAGCCTCACTCA
R-AATAGGTGCCCTGTGACCTG
F-GAAGCAGATCGACCAGAAGG
R-TTCTAGCCGCTTGACAAGGT
F-TGTAACTGGGCTCCTTGCTT
R-TTGCAAAGACCTCTCCTGGT
F-CGACCTCCTCAACTTCAAGC
R-CTGGCTTCCAGTCCTCTCTG
F-GCAAGTACACGGTCCAGGAT
R-GGGATCCATCTGGAGAGACA
F-CGTGATGAGCAACTCCTTCA
R-TGGTCAGCTTCACATTCAGC
F-TCAGTGCCCTTAATTGCTGA
R-CTTGCATAGGTCACGGGTTT
F-CTCCACTTCCTCCTTTGCAG
R-CTTGGGGCTTCAGGATTGTA
F-TCCTTCCCTTTTGGCTTTTT
R-ACCCTCTTCCCGAGTAAGGA
F-TCCGTTTGTTTTGGTGTTGA
R-TACAAGGCTGTCACGGATGA
F-TGGAGCCTACGAAGCTGTTT
R-CCCTCATTAGTTGCGGTGTT
F-ATGAACAGGCCTTCAGCATT
R-AAAGCCTTGCTCCCTACACA
F-CCTTCCACAAGGAACTCCAA
R-GGTAGCTGTTGGTGGGCTAA
F-CTATCCAGAGCGCATCACAA
R-TCCAGGGCTCTTATGTGGTC
F-GGGAGCTCCACACAGAGAAG
R-GCCATCTTCCCATCTTGAAA
F-TGGCTGTACTCCATGAGCAG
R-TCATGGATACTGAGGCACCA
F-AGCAGCCGTCCTTTTGATAA
R-TGCTGGACACCTTTTTAGGG
F-CAGTGTCTACCCCCAAGCAT
R-TTCCATCAAAGACCCTCCAG
F-GGAAACAGCTTGGTGGTGAT
R-TGAGACACGTGAGCAGGAAC

209
210
225
204
164
163
195
200
204
155
249
187
192
236
234
215
187
234
204
228
196
165
235
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Table 1.1 (continued)
Agt

NM_007428

57

F-CACCCCTGCTACAGTCCATT
R-GTCTGTACTGACCCCCTCCA
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Results
Gene expression profiles of the Agtr2-/y brain samples were compared to
profiles of the control brains for two developmental stages, E15 and at birth (P1).
The graphed log ratios by dye swap are presented in Figures 1.4 and 1.5.
Hierarchical clustering of each developmental set demonstrated that the Agtr2-/y
mouse brains had an overall different expression pattern than did those of controls,
as controls and Agtr2-/y samples clustered separately and are shown in Figure 1.6.
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Figure 1.4 Log ratios of all embryo (E15) arrays by dye-swap. X axis = knockouts
labeled blue, controls red; Y axis = knockouts labeled red, controls blue.

Figure 1.5 Log ratios of all postnatal day one (P1) by dye-swap. X axis =
knockouts labeled blue, controls labeled red; Y ax is = knockouts labeled red,
controls blue.
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A

B

Figure 1.6 Hierarchal clustering showing knockout animals have different
expression profiles as represented by the dye swap color coding below the tree. A)
embryo (E15) arrays B) postnatal day one (P1) arrays.
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Data analysis using GeneSpring GX© (FDR ≤ 0.3 and p ≤ 0.001) produced a
list of 133 genes (88 up-regulated, 45 down-regulated) differentially expressed at E15.
A similar analysis (FDR ≤ 0.3 and p≤ 0.005) in newborn brains identified a list of
397 differentially expressed genes (270 up-regulated, 127 down-regulated) in Agtr2-/y
mouse brains. To further narrow the gene lists, genes that had a fold change greater
than or equal to 1.3 and a p-value less than 0.001 in the E15 were selected (Figure
1.3a). This resulted in a list of 62 genes (52 up-regulated and 10 down-regulated) for
the E15 brains (Table 1 .2 and Figure 1.7 and 1.8). In the P1 samples, a fold change
greater than or equal to 1.4 and p-value less than 0.005 was selected for a final list
(Figure 1.3b). This resulted in a list of 62 genes (50 up-regulated and 12 downregulated) in the neonates (Table 1.3 and Figure 1.9 and 1.10). Fold change was
computed with Bioconductor software with a log2 transformation. The final E15
and P1 lists had AK005333 (phosphatidyl decarboxylase) and AK084084 (Rab30) in
common. AK005003 was up-regulated 1.6 fold (p = 1.08E-04) in the E15 and 1.9
fold (p = 3.39E-04) in the P1, while AK084084 was up-regulated 1.5 fold (p =
6.86E-04) in the E15 brains and 1.7 (p = 1.22E-04) in the P1. The E15 list had two
genes listed twice with two separate probes: NM_177054 (Casc4) and NM_033563
(Klf7).
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Figure 1.7 Tile view of final list of up-regulated genes in Agtr2-/y E15 brains. Each
row is an individual array KO red = arrays with Agtr2-/y samples labeled red, KO
blue = arrays with Agtr2-/y samples labeled blue. Expression is represented as a
gradient from red to blue, red being the highest expression and blue being the
lowest. Each column represents an individual gene spot. Gene names are listed
below each column.

Figure 1.8 Tile view of final list of down-regulated genes in Agtr2-/y E15 brains.
Each row is an individual array KO red = arrays with Agtr2-/y samples labeled red,
KO blue = arrays with Agtr2-/y samples labeled blue. Expression is represented as a
gradient from red to blue, red being the highest expression and blue being the
lowest. Each column represents an individual gene spot. Gene names are listed
below each column.
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Table 1.2
Genes at Day E15 Showing Fold Change ≥ 1.3 and p < .001 in Agtr2-/y Brains
Probe set

Genebank

Gene
Symbol

A_51_P514139

NM_027504

Prdm16

A_52_P546610

NM_013626

Pam

A_51_P337944

NM_080708

Bmp2k

A_52_P561377

NM_145505

AI450540

A_52_P542860

NM_172618

Btbd9

A_52_P135424

AK032599

A_52_P654624

AK005333;

Pisd

A_52_P342836

BC055351

AY358078
male
hippocampus

A_52_P150396

AK013803;

A_52_P54666

AK086484;

Mtap2

A_52_P188425

BC047992;

Prosc

A_51_P247114

NM_008199

H2-BL

A_52_P617386
A_51_P393161

AK084084
AK049497

Rab 30
Zfp291

A_51_P496779

NM_194462

Akap9

A_51_P446575

AK044903;

Fnbp1l

A_52_P207132

AK044972;

Plcxd3

A_52_P462472

XM_205178

C77370

A_52_P110581

AK050558;

pancreas islet
cells cDNA

A_51_P212515

NM_178726

Ppm1l

A_51_P227866

AK030696

Txndc13

A_52_P503135

NM_177054

Casc4

Gene Name
PR domain containing
16
peptidylglycine alphaamidating
monooxygenase
BMP2 inducible kinase
expressed sequence
AI450540
BTB (POZ) domain
containing 9
phosphatidyl
decarboxlyase
RIKEN cDNA
2700059D21 gene
microtubule associated
protein2
proline synthetase cotranscribed
histocompatibility 2,
blastocyst

A kinase (PRKA) anchor
protein (yotiao) 9
Formin binding protein
1-like
phosphatidylinositolspecific phospholipase
C, X domain containing
3
expressed sequence
C77370
RIKEN cDNA
A930011G23 gene
protein phosphatase 1
(formerly 2C)-like
Thioredoxin domain
containing 13
RIKEN cDNA
D130060C09 gene

P value

Fold
Change

1.97E-04

+3.1

6.72E-05

+2.1

7.96E-07

+1.9

1.88E-05

+1.9

1.61E-03

+1.8

1.45E-03

+1.6

1.08E-04

+1.6

2.83E-03

+1.6

9.00E-05

+1.6

4.68E-04

+1.6

5.66E-04

+1.5

8.23E-06

+1.5

6.86E-04
1.33E-04

+1.5
+1.5

1.40E-04

+1.5

2.56E-04

+1.4

5.10E-04

+1.4

9.91E-05

+1.4

1.13E-04

+1.4

1.55E-03

+1.4

2.31E-04

+1.4

1.47E-03

+1.4
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Table 1.2 (continued)
A_52_P90101

AK036209;

A_51_P172241

TC1312974

Atxn2

A_52_P660753

XM_194622

Taf1

A_52_P239424

AK086122

Klf7

A_52_P424197
A_51_P366277
A_52_P16346
A_52_P268720

AK029131
BC049166
AK012005;
BC021818

AI585793
Nol8
Sla2
Helz

A_51_P134801

XM_619483

Ankrd12

A_51_P308628

XM_619630

A_51_P128075

NM_027028

Nbeal
Ca binding
riken gene

A_52_P407755

AK009137;

Prei4

A_51_P512340

NM_019840

Pde4b

A_51_P364894

NM_054089

Ncoa6ip

A_52_P462171

XM_354675

Arid4a

A_51_P217878

AK043468;

Mtap1b

A_52_P167166

AK047842;

Shprh

A_52_P540045

AK083897;

Dgkh

A_52_P289071

NM_177054

Casc4

A_51_P115940

NM_172787

L3mbtl3

A_52_P5549

NM_026583

discontinued
record

A_52_P38317

AK046153;

Nat5

A_51_P127215

BC003348;

Sesn3

A_51_P405280

NM_033563

Klf7

A_52_P190807

AK032690

spinocerebellar ataxia 2
homolog (human)
TAF1 RNA poly II
TATA box binding
protein
Kruppel-like factor 7
(ubiquitous)

SRC like adaptor 2
Ankyrin repeat domain
12
Neurobeachin like 1
RIKEN cDNA
1700008P20 gene
Preimplantation protein
4
phosphodiesterase 4B,
cAMP specific
nuclear receptor
coactivator 6 interacting
protein
AT rich interactive
domain 4A (Rbp1 like)
microtubule associated
protein 1B
Diacylglycerol kinase,
ETA
cancer susceptibility
candidate 4
l(3)mbt-like 3
(Drosophila)
RIKEN cDNA
5830415L20 gene
N-acetyltransferase 5
(ARD1 homolog, S.
cerevisiae)
sestrin 3
Kruppel-like factor 7
(ubiquitous)

1.85E-03

+1.4

4.07E-05

+1.4

8.54E-04

+1.4

8.96E-04

+1.4

4.43E-04
1.14E-03
1.93E-04
2.30E-04

+1.4
+1.4
+1.4
+1.4

2.95E-04

+1.4

1.07E-03

+1.4

1.16E-03

+1.4

1.14E-03

+1.4

1.35E-04

+1.3

2.90E-03

+1.3

6.96E-04

+1.3

3.78E-04

+1.3

4.26E-04

+1.3

1.39E-03

+1.3

5.10E-04

+1.3

3.44E-04

+1.3

1.11E-04

+1.3

1.36E-03

+1.3

3.77E-03

+1.3

5.19E-04

+1.3

9.75E-04

+1.3
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Table 1.2 (continued)
A_52_P519538

NM_172712

Ube1l2

A_52_P197199
A_52_P521507
A_52_P621817

XM_139187
BC051169
AK173240

Pcdh9
Trio
Zfp46

A_52_P651784

XM_486486

discontinued
record

A_51_P349008

NM_133783

Ptges2

A_51_P218805

NM_212443

Gfer

A_52_P108808

TC1316888

TC1316888
hypoth.
Protein

A_52_P20639

NM_023727

A_51_P506937

NM_011885

Mrps12

A_51_P432538

NM_010395

H2-t10

A_51_P344566

NM_011121

Plk1

A_51_P272172

NM_053068

Chrac1

A_51_P100246

NM_145578

Ube2m

A_51_P288549

BC016255

Pla2g4b

RIKEN cDNA
5730469D23 gene
protocadherin 9
Trio
similar to Sadenosylmethionine
decarboxylase
prostaglandin E synthase
2
growth factor, erv1 (S.
cerevisiae)-like
(augmenter of liver
regeneration)
RIKEN cDNA
3322402L07 gene
mitochondrial ribosomal
protein S12
histocompatibility 2, T
region locus 10
polo-like kinase 1
(Drosophila)
chromatin accessibility
complex 1
ubiquitin-conjugating
enzyme E2M
phospholipase A2,
group IVB (cytosolic)

1.11E-04

+1.3

2.01E-04
5.54E-04
2.49E-04

+1.3
+1.3
+1.3

1.15E-04

+1.3

3.86E-04

-1.3

9.44E-04

-1.3

5.85E-04

-1.3

2.41E-04

-1.3

5.48E-04

-1.3

5.17E-04

-1.3

2.81E-05

-1.4

3.74E-04

-1.4

1.00E-03

-1.4

1.54E-05

-1.7
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Figure 1.9 Tile view of final list of up-regulated genes in Agtr2-/y P1 brains. Each
row is an individual array KO red = arrays with Agtr2-/y samples labeled red, KO
blue = arrays with Agtr2-/y samples labeled blue. Expression is represented as a
gradient from red to blue, red being the highest expression and blue being the
lowest. Each column represents an individual gene spot. Gene names are listed
below each column.

Figure 1.10 Tile view of final list of down-regulated genes in Agtr2-/y P1 brains.
Each row is an individual array KO red = arrays with Agtr2-/y samples labeled red,
KO blue = arrays with Agtr2-/y samples labeled blue. Expression is represented as a
gradient from red to blue, red being the highest expression and blue being the
lowest. Each column represents an individual gene spot. Gene names are listed
below each column.
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Table 1.3
Genes at P1 Showing Fold Change ≥ 1.4 and p < .005 in Agtr2-/y Brains
Probe Set

Genebank

Gene Symbol

Gene Name

A_51_P222953

AK047664

Gls
1700009P03Ri
k

RIKEN cDNA
1700009P03 gene

A_52_P329105

NM_134077

A_52_P386075
A_51_P304449

XM_622182
AK031960

Add1

A_51_P390755

AK035845

Ptprs

A_52_P654624

AK005333

Pisd

A_52_P657817

AK030767

Mapk8

A_52_P368881
A_52_P102630

TC1323355
AB063319

Rian

A_52_P320822

NM_177199

Sfrs10

A_52_P236097

AK017529

Sf3b3

A_52_P92213

AK089867

A_52_P386468

NM_007700

Chuk

A_52_P475033
A_52_P617386
A_52_P422088

AK088515
AK084084
AK084846

A_52_P440027

AK014565

A_52_P24835

NM_027893

Pvrl4

A_52_P484519

AK171368

Sept 11

A_52_P319752

AK046219

Nudcd3

A_52_P527329
A_51_P183154
A_52_P955951

AK089867
AK049897
AK048907

Hook1
Gria4

Rab 30
Ptbp2
4632411B12Ri
k

A_52_P340618

BC030361

Eml5

A_52_P323215

NM_019570

Rev1l

RIKEN cDNA
9630010G10 gene
RIKEN cDNA
4933439C20 gene
mitogen activated
protein kinase 8

RIKEN cDNA
5730405G21 gene
splicing factor 3b,
subunit 3
conserved helixloop-helix
ubiquitous kinase

PTBP2
RIKEN cDNA
4632411B12 gene
poliovirus receptorrelated 4
NudC domain
containing 3

echinoderm
microtubule
associated protein
like 5
REV1-like (S.
cerevisiae)

8.890E-06

Fold
Change
+2.2

4.510E-03

+2.1

1.040E-03
1.270E-04

+2.1
+2.0

1.380E-04

+2.0

3.390E-04

+1.9

5.090E-04

+1.9

3.770E-04
4.280E-04

+1.9
+1.8

7.950E-04

+1.8

7.340E-04

+1.8

8.570E-04

+1.7

2.200E-06

+1.7

9.930E-04
1.220E-04
5.190E-04

+1.7
+1.7
+1.7

9.200E-04

+1.6

5.330E-04

+1.6

8.820E-04

+1.6

4.860E-04

+1.6

8.570E-04
6.280E-04
2.170E-04

+1.6
+1.6
+1.6

7.360E-04

+1.6

3.080E-05

+1.6

P Value
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Table 1.3 (continued)
A_52_P433
A_52_P671465
A_51_P458230
A_52_P276412

AK129392
AK051363
AK054427
AK011886

A_52_P620432

AK019968

A_52_P398494
A_52_P113585

XM_902635
AK084575

A_52_P411015

NM_177300

A_52_P61903
A_52_P182520
A_52_P668157

AK014174
BC028435
AK011905

Atpif1
2410005O16R
ik
Ankrd11
Hdh
B130040O20
Rik
Chka
Timm9
Ncam1

A_52_P124105

AK083451

Rab14

A_52_P98160
A_52_P188026
A_52_P59544

TC268598
BC051052
AK036220

Ccar1
Rbm18

A_52_P72938

AK039096

AI790442

A_52_P321318

AF093677

mt-Atp6

A_52_P236607

BC066170

Ercc8

A_52_P289213
A_52_P454703

BC059256
BE650851

Notch2

A_51_P358256

NM_009803

Nr1i3

A_52_P171993

AK012463

Psmd7

A_52_P146848

NM_016690

Hnrpdl

5.040E-04
2.720E-04
8.970E-04
6.450E-04

+1.6
+1.6
+1.6
+1.6

6.000E-04

+1.6

7.040E-04
1.000E-04

+1.5
+1.5

6.150E-04

+1.5

4.240E-04
3.110E-04
8.800E-05

+1.5
+1.5
+1.5

RAB14, member
RAS oncogene
family

1.110E-04

+1.5

CCAR

5.940E-04
3.710E-04
3.110E-04

+1.5
+1.5
+1.5

8.760E-04

+1.5

3.140E-04

+1.5

3.100E-04

+1.4

8.250E-04
3.580E-04

+1.4
+1.4

6.810E-04

+1.4

7.320E-04

+1.4

2.740E-04

+1.4

Gpiap1

RIKEN cDNA
2410005O16 gene
HDH
RIKEN cDNA
B130040O20 gene
choline kinase alpha

expressed sequence
AI790442
ATP synthase 6,
mitochondrial
excision repairosscomplementing
rodent repair
deficiency,
complementation
group 8
Notch2
nuclear receptor
subfamily 1, group
I, member 3
proteasome
(prosome,
macropain) 26S
subunit, nonATPase, 7
heterogeneous
nuclear
ribonucleoprotein
D-like
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Table 1.3 (continued)
A_52_P237755
A_52_P860487

TC1517524
ac1158020

A_51_P122246

NM_029720

Creld2

A_51_P281255

NM_016777

Nasp

A_52_P576863

NM_025922

Itpa

A_51_P259001

NM_029814

Chmp5

A_52_P476357

NM_016878

Dnpep

A_52_P141786

NM_029561

Ndfip2

A_51_P349142
A_51_P479802

NM_007991
XM_110248

Fbl
Fbxo11

A_51_P125535

NM_017374

Ppp2cb

A_51_P132978

NM_010497

Idh1

A_51_P117226

AK046533

A_51_P267544

NM_013522

Frg1

RIKEN cDNA
5730592L21 gene
nuclear
autoantigenic sperm
protein (histonebinding)
inosine
triphosphatase
(nucleoside
triphosphate
pyrophosphatase)
RIKEN cDNA
2210412K09 gene
aspartyl
aminopeptidase
Nedd4 family
interacting protein 2
fibrillarin
F-box protein 11
protein phosphatase
2a, catalytic subunit,
beta isoform
isocitrate
dehydrogenase 1
(NADP+), soluble
FSHD region gene
1

8.580E-04
6.740E-04

+1.4
+1.4

3.360E-04

-1.4

1.840E-04

-1.4

8.830E-04

-1.4

3.150E-04

-1.4

8.290E-04

-1.4

3.940E-04

-1.4

1.640E-04
2.630E-05

-1.4
-1.4

5.120E-04

-1.6

7.520E-04

-1.6

1.020E-04

-1.6

6.180E-04

-1.6

Randomly selected genes from each list (Table 1.1) were validated by
quantitative RT-PCR. In the majority of cases the fold change levels found by RTPCR correlated well with the expression profile array data (Tables 1.4 and 1.5).
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Table 1.4
RT-PCR Results of Selected Genes at E15
Probe ID
a_51_P514139

Primary Accession
NM_027504

a_51_P337944

NM_080708

a_52_P654624

AK005333

a_52_P150396

AK013803

a_52_P188425

BC047992

a_52_P462472

XM_205178

a_52_P110581

AK050558

a_51_P396325
A_52_P54666
a_52_P503135
a_52_P289071
a_52_P407755
a_51_P100246
a_51_P488673
a_52_P404108
a_51_P473533

FC
3.1

RT-PCR FC
1.3

1.9

1.4

1.6

2.3

1.6

no change

1.5

1.1

1.4

no change

1.4

no change

NM_013681
AK086484

Gene Name
Prdm16
Bmp2 inducible
kinase
Pisd
RIKEN CDNA
2700059D21 GENE
proline synthestase
expressed seq.
C77370
RIKEN CDNA
A930011G23
GENE
synapsin 2
Mtap2

1.3
1.6

1.3
1.3

NM_177054

Casc4

1.4

1.2

AK009137
NM_145578

Prei4
Ube2m

1.4
-1.4

1.7
-1.2

NM_008143

Gnb2L1

-1.3
-1.2

-1.5

L32836

Ahcy

-1.2

-1.7

Table 1.5
RT-PCR Results of Selected Genes at Postnatal Day 1
Primary Accession
AK047664
NM_134077
AK031960
AK005333
AK017529
NM_007700
AK051363
AF093677

Gene Name
Glutaminase
Rbm26
Adducin 1 (alpha)
Pisd
splicing factor 3b
Conserved helix
loop helix
Gpi-anchored
membrane protein 1
ATP synthase 6

Probe ID
a_51_P222953
a_52_P329105
a_51_P304449
a_52_P654624
a_52_P236097

FC
2.2
2.1
2
1.9
1.8

RT-PCR FC
1.4
1.3
1.7
1.7
1.4

a_52_P386468

1.7

1.4

a_52_P671465

1.6

1.7

a_52_P321317

1.5

no change
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Table 1.5 (continued)
NM_008143
NM_017374
NM_013522
NM_016777

Gnb2L1
Protein
phosphastase2cb
Frg1
Nasp

a_51_P488673
a_52_P404108

1.0
-1.0

No change

a_51_P125535

-1.6

-1.4

a_51_P267544
a_51_P281255

-1.6
-1.4

-1.7
-1.3

The expression of genes involved in the renin-angiotensin pathway was also
examined by RT-PCR and microarray values. No significant differences were found
for these genes at either time point on the arrays (Table 1.6).

Table 1.6
Comparison of E15 and P1 Values of Renin-Angiotensin System Genes

Gene
Agtr2
Agtr1
Agtr1b
Ace

Agtrl1
Agtrap

Ace2
Ren1

spotnumber
A51P437978
A51P236439
A52P645862
A52P53617
A52P72297
A51P310523
A52P68028
A52P97572
A51P299055
A52P330667
A51P271208
A52P552550
A52P480709
A51P257496
A52P652885

E15
RT-pvalue
.1
.84

.65

E15
Array
pvalue
0.92
0.92
0.79
0.86
0.88
0.93
0.84
0.71
0.98
0.73
0.76
0.95
0.98
0.93
0.84

E15
Array
fold
chg
0.9
0.97
1.08
1.03
1.03
1.06
0.95
0.89
1
0.94
1.06
0.98
1.01
1.02
1.04

P1
RT
Pvalue
.04
.32

.16

.32

P1 array
pvalue
0.741
0.85
0.99
0.98
0.91
0.95
0.94
0.99
0.92
0.96
0.81
0.92
0.81
0.936
0.96

P1 Array
foldchange
1.23
0.94
0.98
0.98
0.95
1.07
0.94
1.01
1.04
1.03
1.08
0.97
1.11
0.97
0.96
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Table 1.6 (continued)

Renbp
Agt

A52P544060
A51P316661
A51P123765
A51P323712
A51P436690

.37

0.86
0.57
0.44
0.92
0.94

0.96
1.2
0.88
1.02
0.98

.51

0.95
0.98
0.99994
0.988
0.96

0.96
1.02
1
1.06
0.96

A list of 388 genes was also produced that were found NOT to be expressed
at either time point (data not shown). Data analysis also revealed that there were 694
genes with no expression in the embryos and 862 genes not expressed in the P1 (data
not shown). These genes were involved in a variety of physiological processes
and/or cDNAs from adult tissues.
To create a list of genes that were significantly differentially expressed at
both developmental stages and to investigate which genes expression was affected by
developmental stage, a two way ANOVA analysis was performed. This analysis used
developmental age and absence of Agtr2 as parameters and a Benjamini and
Hochberg false discovery rate of 0.05. This created a list of 118 (87 up and 31 down)
differentially regulated genes in all knockouts and 3 (2 up and 1 down in neonates)
differentially regulated genes for developmental stage (table 1.8).

The list of

differentially regulated genes in all Agtr2-/y mouse brains was compressed to 82
genes, by eliminating genes with less than a 1.3 fold change (Table 1.7). This list had
15 genes in common with the E15 t-test list and 16 genes in common with the P1 ttest list.
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Table 1.7
Significantly differentially regulated genes in Agtr2-/y ANOVA FDR=.05,
fold change ≥ 1.3
Probe

Genebank

A_52_P386075

AK004071

Gene
symbol

A_52_P654624

AK005333;

A_52_P561377

NM_145505

A_52_P381009

AK009502;

Tia1

A_52_P82704

AK122557

Bcl11a

A_52_P617386
A_52_P368881
A_51_P222953
A_52_P54666
A_51_P337944
A_52_P564625
A_52_P135424
A_51_P247114

AK084084
TC1323355
AK047664;
AK086484;
NM_080708
TC1362404
AK032599
NM_008199

Rab 30

A_52_P150396

AK013803;

A_52_P236097
A_51_P136820
A_52_P504460

AK017529;
NM_011179
AK013634;
NM_001004
146
AK005295;

A_52_P372843
A_52_P320822

NM_177199

A_52_P280448
A_52_P342836
A_51_P183154
A_52_P422088
A_52_P4148
A_52_P167166
A_52_P623457
A_51_P172241

TC1254974
BC055351
AK049897
AK084846;
BC056964
AK047842;
NM_178922
TC1312974

A_52_P90101
A_52_P360453

FC
+1.9

4933439C20
Rik
AI450540

A_51_P154668

Common Name

RIKEN cDNA 4933439C20 gene

+1.7

expressed sequence AI450540
cytotoxic granule-associated RNA
binding protein 1
Mus musculus mRNA for
mKIAA1809 protein

+1.7
+1.7
+1.7

Bmp2k

BMP2 inducible kinase

H2-Bl
2700059D21
Rik
Sf3b3
Psap
Ccnt2

histocompatibility 2, blastocyst

+1.6
+1.6
+1.6
+1.6
+1.6
+1.6
+1.6
+1.6

RIKEN cDNA 2700059D21 gene

+1.5

splicing factor 3b, subunit 3
Prosaposin
cyclin T2
similar to phosphatidylserine
decarboxylase

+1.5
+1.5
+1.5

MGC65558

+1.5
+1.5

5730405G21
Rik

RIKEN cDNA 5730405G21 gene

AY358078
Hook1
Ptbp2

+1.5
+1.5
+1.5
+1.5
+1.4
+1.4
+1.4
+1.4
+1.4

Hic2

hypermethylated in cancer 2

AK036209;

Sca2

spinocerebellar ataxia 2 homolog
(human)

+1.4

AK084271;

3110052M02
Rik

RIKEN cDNA 3110052M02 gene

+1.4
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Table 1.7 (continued)
A_52_P102022

AK017641;

A_52_P369946

CB850089

5730446C15
Rik

+1.4
+1.4

9030221M09
Rik
2310032D16
Rik
D930046L20
Rik

A_51_P461947

NM_177298

A_52_P407755

AK009137;

A_52_P499917

AK051838;

A_52_P386468

NM_007700

Chuk

A_52_P481097
A_51_P458230
A_52_P676492
A_52_P432464
A_52_P1100217
A_52_P337948
A_52_P323215
A_52_P6451
A_52_P374669
A_52_P190807
A_52_P276412

AK086528;
AK054427;
AK032320
AK053863;
AK051484;
AK088459
NM_019570
AK090341
XM_359326
AK032690
AK011886;

Lztfl1

A_52_P456702

AK045162;

A_52_P376103

AK042630;
BC019581;X
M_619603

A_52_P273674

RIKEN cDNA 5730446C15 gene

RIKEN cDNA 9030221M09 gene

+1.4

RIKEN cDNA 2310032D16 gene

+1.4

RIKEN cDNA D930046L20 gene

+1.4

conserved helix-loop-helix ubiquitous
kinase

+1.4

Brd8
Luc7l2

LUC7-like 2 (S. cerevisiae)

Tnik
Rev1l

REV1-like (S. cerevisiae)

Jarid1a
Atipif11
B930046C15
Rik

RIKEN cDNA B930046C15 gene

+1.4
+1.4
+1.4
+1.4
+1.4
+1.3
+1.3
+1.3
+1.3
+1.3
+1.3
+1.3
+1.3

4930413O22
Rik
5830415L20
Rik
Leng8
9030025P20
RIK

A_52_P5549

NM_026583

A_52_P61273

BC066768

A_52_P527329

AK089867;

A_52_P577116

AK029399;

Pik3ca

A_51_P476660

XM_139743

Mllt4

A_52_P268720
A_52_P107681

AK122645
AK028731;

A_51_P221008

AK028276;

Helz
Ylpm1
3222401L13
Rik

A_51_P133037

NM_008889

Ppp1r14b

RIKEN cDNA 4930413O22 gene

+1.3

RIKEN cDNA 5830415L20 gene

+1.3
+1.3
+1.3

phosphatidylinositol 3-kinase,
catalytic, alpha polypeptide
myeloid/lymphoid or mixed lineageleukemia translocation to 4 homolog
(Drosophila)

+1.3
+1.3

YLP motif containing 1

+1.3
+1.3

RIKEN cDNA 3222401L13 gene

+1.3

protein phosphatase 1, regulatory
(inhibitor) subunit 14B

+1.3
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Table 1.7 (continued)
A_52_P668157

AK011905;

A_52_P342202

NM_027696

A_52_P283055

TC1248463

NCAM1
4933425I22R
ik

NM_139144

A_52_P620432

AK019968;

A_51_P192089
A_52_P507277

NM_028228
NM_025789

2410005O16
Rik
Pinx1
Rshl2

A_51_P486479

NM_024456

Rab5c

A_51_P267544
A_51_P110576
A_51_P261689
A_52_P476357

NM_013522
NM_011175
AK003078;
NM_016878

Frg1
Lgmn
UBE2S
Dnpep

A_51_P439824

NM_018771

Rgs19ip1

A_52_P461292
A_51_P261351
A_52_P614336

NM_008753
NM_026246
NM_011116

A_51_P140141

AK013263;

Oaz1
Mrpl49
Pld3
1500019G21
Rik

A_51_P375227

NM_009954

A_52_P187787
A_51_P435333
A_52_P585104

BC025640;X
M_130932
NM_023231
NM_027151
NM_010219

+1.3

RIKEN cDNA 4933425I22 gene

+1.3
+1.3

A_51_P261107

A_52_P362128

Neural cell adhesion molecule1

Ogt

O-linked N-acetylglucosamine
(GlcNAc) transferase (UDP-Nacetylglucosamine:polypeptide-Nacetylglucosaminyl transferase)

+1.3

RIKEN cDNA 2410005O16 gene

+1.3

PIN2/TRF1-interacting protein
radial spokehead-like 2
RAB5C, member RAS oncogene
family
FSHD region gene 1
legumain

+1.3
-1.3

aspartyl aminopeptidase
regulator of G-protein signaling 19
interacting protein 1
ornithine decarboxylase antizyme
mitochondrial ribosomal protein L49
phospholipase D3

-1.3
-1.3
-1.3
-1.3
-1.3
-1.3
-1.3
-1.3
-1.3

RIKEN cDNA 1500019G21 gene

-1.3

Bcar1

breast cancer anti-estrogen resistance
1

-1.3

Pygo2

pygopus 2

-1.3

Stoml2
Dctn2
Fkbp4

stomatin (Epb7.2)-like 2
dynactin 2
FK506 binding protein 4

-1.3
-1.4
-1.4
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Table 1.8
Significantly differentially expressed genes by developmental stage ANOVA FDR .05

A_51_P431397
A_52_P98630

P
Value
0.0199
0.0195

A_51_P314161

0.0195

Probe Set

Gene Name

Gene Symbol

Genebank

Nucleoporin 214
interleukin 3
queuine tRNAribosyltransferase 1

Nup214
Il3

AK040284
NM_010556

Expression
with age
Down
Up

Qtrt1

NM_021888

Up

Discussion
Angiotensin II binds to two receptors, AGTR1 and AGTR2. In the absence
of AGRT2, it would be expected that all angiotensin II would be bound to AGTR1.
Without the regulating effect of AGTR2, the AGTR1 signaling cascades should be
unchecked. The absence of AGTR2 did not cause a detectable increased expression
of AGTR1 in the brains of E15 or P1 Agtr2-/y mice. There was also no difference in
expression of genes in the RAS between knockouts and controls. Our results show
that genes downstream of AGTR1 are up-regulated in the absence of AGTR2.
Our results also suggest that AGTR2 may have different effects on the
developing brain at different developmental stages as only two genes, Pisd and Rab
30 were found to be in common between the two developmental stages in the final
lists of significantly differentially expressed genes.
The largest gene categories represented as over-expressed in E15 Agtr2-/y
brains are transcription factors and genes in the AGTR1 pathway (Table 1.9). Other
categories of genes are transferases, kinases, genes involved in microtubule and actin
processing, cell adhesion, protein transport and/or binding, nucleic acid binding,
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immunity, cell cycle arrest, ubiquitin/proteasome function and a protein
phosphatase. Two genes, Akap9 and Mtap2 are involved in the up-regulation of
NMDA receptors (Lin et al. 1998).
In the E15 Agtr2-/y brains, genes predominantly involved in apoptosis were
found to be down-regulated. This is consistent with previous findings that AGTR2
is a mediator of apoptosis (Yamada et al. 1996). A summary of functions for
dysregulated genes in the E15 knockouts is presented in Table 1.9 and Table 1.10.
Table 1.9
Up-regulated Gene Categories of E15 Agtr2-/y Brains
Agtr1-related Functions
Pisd
Pde4B
Plcxd3
Prei4
Dgkh
Sla2
Ca2+ binding Riken

Transferases
Ncoa6Ip
Dgkh
Nat5
Trio

Transcription Factors
Prdm16
L3mbtl3
Zfp291
Zfp46
C77370
Aff3
Taf1
Klf7
Arid4a

Kinases
Bmp2k
Akap9

Microtubules/Actin
Mtap2
Fnbpi1
Mtap1B
Akap9

Cell Adhesion
Btbd9
Pcdh9
Sla2
Cell Cycle Arrest
Sesn3

Nucleic Acid Binding
Nol8
Helz
Trio
Ubiquitin/Proteasome
Ube1l2

Protein
Transport/Binding
Pam
Nbeal1
Rab30
Ncoa6Ip
Atxn2
Shprh
Immunity
H2-Bl
Sla2
Protein Phosphatase
Ppm1l
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Table 1.10
Down-regulated Gene Categories of E15 Agtr2-/y Brains
Agtr2-related Functions
Ptges2
Pla2g4b
Ube2m
Cell Proliferation
Gfer

Cell Cycle Arrest
Plk1

Transferase
Plk1
Chrac1

Translation
Mrps12

Immunity
H2-t10

Up-regulated genes in the P1 Agtr2-/y brains were over-represented by genes
involved in protein binding and transport (Ercc8, Notch2, Hdh, Timm9, Rev1l,
Rab14, Rab30, Sept11 and Hook1). Also up- regulated were genes involved in RNA
processing, (Rbm26, Rbm18, Sfrs10, Rian, Sf3b3, Hnrpd1), DNA binding, (Ankrd
11, Rab14, Ccar1), transcription (Prr8, Ercc8, Nr1i3) and glutamate metabolism (Gls
and Gria4). Several genes involved in cell adhesion (Ptprs, Pvr14, Ncam1 and Nrli3)
as well as cytoskeleton and microtubule expression (Add1, Hook1 and Eml5) were
also represented. A complete summary of the categories is found in Table 1.11.
Examination of the P1 results show that some of the genes involved histone
modification (Nasp and Ppp2cb), nucleotide metabolism (Itpa), NADP+ activity
(Idh1), protein ubiquination (Fbox11 and Ndfip2) rRNA processing (Frg1),
chromatin remodeling (CHMP5) and calcium ion binding (Creld1). The list is
summarized in Table 1.12.
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Table 1.11
Functions of Up-regulated Genes of P1 Agtr2-/y Brains
Agtr1 Pathway
Mapk8
Pisd
Chka

Cell Adhesion
Ptprs
Pvr14
Ncam1
Nrli3
Transcription
Prr8
Ercc8
Nr1i3
Anti-apoptosis
Hdh
Notch2
Glutamate
Metabolism
Gls
Gria4

Protein Binding/Transport
Ercc8
Rab30
Notch2
Rab14
Hdh
Sept11
Timm9
Hook1
Rev1L

RNA Processing
Rbm26
Rbm18
Sfrs10
Rian
Sf3b3
Hnrpdl
Cytoskeleton/Microtubules DNA Binding
Add1
Ankrd 11
Hook1
Rab14
Eml5
Ccar1
Cell Cycle Control
Nudcd3
Atpif1
Gpiap1
Ccar1
Perception of Sound
Timm9
Ercc8
Protein Phosphatase
Ptprs

Kinases
Mapk8
Chuk
Ubiquitin/Proteasome
Usp15
Psmd7

Table 1.12
Functions of Down-regulated Genes of Agtr2-/y P1 Brains
Chromatin Remodeling
Chmp5
Lysosome Organization
Chmp5
Protein Modification
Zdhhc2
NADP+ Activity
Idh1

Histone Binding
Nasp
Ppp2cb
Proteolysis
Dnpep
rRNA Processing
Fbl

Nucleotide Metabolism
Itpa
Protein Ubiquination
Fbxo11
Ndfip2
Ca2+ Binding
Creld2
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Pathway Studio (Ariadne, Rockville, MD USA) was used to visualize
common functions for the genes down-regulated in the E15 Agtr2-/y brains. Three
genes down-regulated in E15 Agtr2-/y brains Ptges2, H2-T10 (HLA-F) and Ube2m,
are all involved in inducing apoptosis (Figure 1.11), consistent with previous findings
that AGTR2 induces apoptosis. Plk1 has been shown to cause cell proliferation and
inhibit apoptosis (Reagan-Shaw and Ahmad 2005; Jang et al. 2006). Pla2g4b is a
phospholipase and phospholipases are in the AGTR2 signaling pathway.

Figure 1.11 E15 down-regulated genes involved in apoptosis. Yellow squares = cell
functions, pink shapes = proteins, purple gradient = E15 list.
Examining the genes up-regulated in the Agtr2-/y E15 brains with 1.5 fold or
greater expression reveals a complex picture. AGTR2 has previously been shown to

45

down-regulate MAP1B but up-regulate MAP2 in PC12W cells (Stroth et al. 1998). In
this study Mtap2 and Mtap1b are both up-regulated in the E15 Agtr2-/y brains.
MAP2 (Mtap2) has previously been shown to be phosphorylated by JNK and
subsequently defines dendritic shape in the brain (Bjorkblom et al. 2005) Map2 is
found in the dendrites and is crucial for microtubule stability (Stroth et al. 1998).
Map1b is found in growth cones and is needed for neurite outgrowth (Stroth et al.
1998). It remains to be seen if these two genes (Mtap2 and Map1b) play a role in
the defective dendritic spine morphology noted in Agtr2-/y mice (Maul, unpublished
data). These genes also regulate actin along with two genes C1orf39 (also known as
Fnbp1l) (Ho et al. 2004) and Sla2 (Sun et al. 2005) which are also up-regulated in
E15 Agtr2-/y brain. Several other up-regulated genes, Akap9, Fnbp1l, as well as
Mtap2 and Map 1B are associated with microtubule function (Figure 1.12).
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Figure 1.12 Genes up-regulated in Agtr2-/y brains affecting microtubule expression
as well as other cell functions vital to brain development and function. Genes
highlighted in purple are from the E15 list. (FLJ20274 = Fbl) Yellow squares = cell
function, orange hexagons = functional class, pink ovals = proteins, gray ovals =
cell part
Peptidylglycine alpha-amidating monooxygenase (Pam), was found to be
more than two-fold up-regulated in the E15 knockouts (Table 1.2). This gene
contains two catalytic domains that work sequentially to catalyze neuroendocrine
peptides and is needed for signal transduction and receptor recognition (Driscoll et
al. 2006).
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Prdm16, PR domain containing 16, (also known as Mel 1) shared the highest
level of expression in the E15 knockouts. This gene codes for a transcription factor
containing several zinc finger domains and is associated with myelodysplastic
syndrome and acute myloid leukemia(Nishikata et al. 2003; Xinh et al. 2003). Several
zinc fingers and helicases are up-regulated in the E15 knockouts: Zfp291, Zfp46,
Helz and Shprh.
Genes involved in regulation of microtubules are also well represented in the
over-expressed genes of the P1 knockouts. Add1, Eml5, Hdh, Hook1, Nudcd3 and
Sept11 all affect microtubules.
Notch2 and Hdh are up-regulated in P1 knockouts and both have antiapoptotic effects (Rigamonti et al. 2000; Duechler et al. 2005; Leavitt et al. 2006).
Hdh up-regulates brain derived neurotrophic factor (BDNF) (Zuccato et al. 2003)
and associates with the EGF pathway potentially causing overgrowth of neuronal
cells. Notch2 is also negatively associated with glial differentiation (Tanaka et al.
1999).
In the P1 knockouts several overexpressed genes, Hdh, Gria4, and Gls, were
found to be involved in glutamate metabolism. Glutamate metabolism is integral to
NMDA receptors which are essential in neuronal development and synaptic
plasticity.
Down-regulated in the P1 brains are Fbox11 and Ndfip2, which are involved
in the ubiquitin-proteasome system which contributes to cellular differentiation (Li et
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al. 2007). Also down-regulated in the P1s are Nasp and Snf7 which are involved in
histone modification. Cells preparing to undergo apoptosis often have histone
modification (Janigro 2006). Several other genes involved in Agtr2 functions, such
as two phosphataseses, Itpa and Pp2cb are also down-regulated in the P1 brains.
Idh1 and Ndfip2 are genes involved in the NF-Kappa pathway in apoptosis. Fbl and
Frg1 are involved in RNA processing, and are also nucleolar proteins.
Mapk8, map kinase 8, (also known as JNK1) is part of the AGTR1
signaling cascade and is one of the most significantly up-regulated genes in the P1
knockout brains. It has been shown to be a regulator of morphogenesis in early
nervous system development (Tararuk et al. 2006). JNK1 (Mapk8) phosphorylates
the microtubule depolymerizing factor SCG10 which determines microtubule
stability and axodendritic length (Tararuk et al. 2006).
The up-regulation of Chuk (also known as IKK1) is significant in that it is
also influenced by angiotensin II (Wu et al. 2006), and activates the NF-kappa-B
complex, which in turn causes cell proliferation and anti-apoptotic effects (Luo et al.
2005). (Figure 1.13).
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Figure 1.13 Interaction and common targets of Chuk, Agtr1 and Agtr2. Note that
Chuk, Agtr2 and Agtr1 up-regulate cell proliferation, but also are involved in
apoptosis. Purple shapes = genes from P1 list, pink shapes = proteins, orange
hexagons = functional classes, yellow squares = cellular functions.
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Other important up-regulated genes in the P1 list are cell adhesion genes.
Ncam1, neural cell adhesion molecule 1, has been associated with NMDA receptors
(Sytnyk et al. 2006) and the inhibition of cell death (Bussolati et al. 2006). Pvrl4 is
also a cell to cell adhesion gene (Reymond et al. 2001). Ncam1, Gria4, Nr1i3 and
Mapk8 all share several important neurological functions (Figure 1.14).

Figure 1.14 Genes with common neurological functions that are up-regulated in P1
knockouts. Purple shapes = genes from P1 list, pink shapes = proteins, orange
hexagons = functional classes, yellow squares = cellular functions
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It is important to note that this study used total RNA isolated from whole
brain for gene expression profiling. Previous in-situ hybridization work (Nuyt et al.
1999) has shown that Agtr2 gene expression is varied in both expression level and
location dependent upon developmental stage.

In-situ hybridization of the

dysregulated genes may further elucidate potential roles of these genes in the
developing brain.
Our study shows that the absence of Agtr2 gene expression in the developing
brain causes an up-regulation in AGTR1 activities such as cell proliferation. A more
novel finding for both developmental stages E15 and P1 is genes connecting with
NMDA receptor function are increased in the Agtr2-/y brain, and may possibly
contribute to abnormal brain development. The up-regulation of genes involved in
cell adhesion point to a contribution to abnormal synaptic connectivity. Our results
support other studies that have shown abnormal dendritic spines in Agtr2-/y mice
might be caused by abnormal microtubule activity. We found genes that affect
micro-tubules are up-regulated at both developmental stages in the Agtr2-/y mouse
brains. This study further adds to the hypothesis that AGTR2 contributes to the
developing brain by influencing cell morphology and synaptic connectivity. Further
analysis might reveal if some of the genes influenced by AGTR2 may also contribute
to the pathophysiology of mental retardation.
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IDENTIFICATION OF AGTR2 INTERACTING PROTEINS
IN FETAL BRAIN
Many genes can have different expression patterns and functions depending
on the developmental state of the organism. Genes expressed in the brain during
embryonic and fetal development can be different than those expressed in the adult
brain. Understanding the interactions of different proteins in the developing brain is
important to understanding the etiology of mental retardation (MR), which affects
approximately 1-3% of the population (Chelly and Mandel 2001) and brain
development.
The angiotensin II type receptor (AGTR2) is a seven transmembrane
receptor consisting of 363 amino acids (Mukoyama et al. 1993). The AGTR2 gene is
located on human chromosome Xq23 and consists of 3 exons (Gard 2002). It is
expressed at high levels in fetal brain (Nuyt et al. 1999), but is predominately
expressed in the cerebellum of the adult brain, though it is up-regulated in some
cases of neurological disease (von Bohlen und Halbach and Albrecht 2006).
Angiotensin II has been shown to affect not only physiological behaviors related to
water intake, but also affecting cognition and emotional centers (Gard 2002).
Several mutations in AGTR2 have been characterized in humans. Specifically, a
G21V mutation in the N-terminal, an A324G and I337V mutations in the C-terminal
and a FSPhe133 deletion and I53F mutation in the transmembrane domain have been
described in individuals with MR(Vervoort et al. 2002; Ylisaukko-ojo T 2004). Also,
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several proteins (Erb3, PLZF, ATIP, NHE6) have been found to interact with
AGTR2 through in-vivo and in-vitro studies (Knowle et al. 2000; Senbonmatsu et al.
2003; Nouet et al. 2004; Pulakat et al. 2005).
The amino terminal of AGTR2 has been shown to be necessary for the binding
of angiotensin II (Yee et al. 1998). The second intracellular loop of AGTR2 is
necessary for G-protein signaling (Moore et al. 2002). Studies using Xenopus oocytes
showed that the C-terminus of the 3rd intracellular loop of AGTR2 is necessary to
lower cGMP levels mediated by AGTR2 and that the C-terminal tail is necessary for
negative regulation of cGMP (Pulakat et al. 2005). Previous yeast two-hybrid
studies have found that the 3rd intracellular loop of AGTR2 interacts with v-erb-b2
erythroblastic leukemia viral oncogene homologue, (ERBB3) (Knowle et al. 2000),
and solute carrier family 9 Na/H exchanger isoform 6, (NHE6) (Pulakat et al. 2005).
The C-terminal domain has been found to interact with promyelocytic leukemia zinc
finger protein (PLZF) (Senbonmatsu et al. 2003) and AGTR2 interacting protein,
(ATIP) (Nouet et al. 2004).
In light of these findings, our goal is to identify proteins that interact with
AGTR2 in the developing brain and to further understand AGTR2 mediated
signaling in developing brain. Using a yeast two hybrid system, individual constructs
of either the amino or carboxy terminal of AGTR2 were made and screened against
a human fetal brain cDNA library. Here we describe the interaction between the
amino terminal of AGTR2 and three proteins: ASMTL, GNB2L1 and NGLY1.
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Materials and Methods
Cloning vector and Yeast Strains: The Saccharomyces cerevisiae strain AH109 (Ade-,
Met+, Trp-, Leu-, His-) was used from the MATCHMAKER Gal4 2-Hybrid System
Three (Clontech). The plasmid pGBKT7 (Clontech) two-hybrid bait vector was
used to express a protein of interest in fusion with the GAL4 binding domain (BD)
and the interacting protein. It contains a kanamycin resistance gene for selection in
E. coli, and when transformed into yeast it is prototrophic for tryptophan. The
plasmid pACT2, a yeast two-hybrid prey vector (CLONTECH) was used to
construct translational fusions of the GAL4 activation domain (AD) and the protein
of interest. It contains an ampicillin resistance gene for selection in E. coli, and is
prototrophic for leucine when transformed into the AH109 strain.
Construction of bait vectors: Primers were designed with an EcoRI adapter
sequence to make a PCR product of the first 45 amino acids of AGTR2 and a
separate primer set for the last 52 amino acids of AGTR2. The amplicon was ligated
into the PCR2.1 vector (Invitrogen). Positive clones were selected and cultured in
LB with 20ng/ml of ampicillin. Plasmid DNA from selected clones was isolated
with Qiagen Mini-prep kits according to manufacturer instructions (Qiagen).
Plasmids were sequenced using M13 primers, F- 5’ CTGGCCGTCGTTTTAC 3’
and R- 5’ GTCATAGCTGTTTCCTG 3’ and DYEnamic Dye Terminator Cycle
sequencing Kit (GE Healthcare) using the automated MegaBACE 1000 DNA
Analysis system (GE Healthcare). Sequences were analyzed using the DNASTAR
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program (Madison, WI). Plasmid DNA was digested with EcoRI (New England
Biolabs), electrophoresed and the desired insert was gel isolated and ligated into an
EcoRI digested pGBKT7 plasmid. Ligation was achieved using the Ligate-IT Rapid
Ligation Kit (USB) according to manufacturer instructions. Plasmid DNA was
isolated from positive clones. The DNA was sequenced to verify that they were inframe with the Gal4 binding domain of pGBKT7. The bait constructs containing
AGTR2 gene inserts were transformed using the LiCl method into yeast strain
AH109 (Clontech) according to manufacturer’s instructions. After transformation,
yeast was plated on SD media without tryptophan which selects for the pGBKT7
plasmid. To verify that the desired proteins were being produced, proteins from
the transformed yeast of each construct were harvested and purified according to
manufacturer instructions (Clontech 1999). Proteins were electrophoresed on a
12% SDS-Page acrylamide gel, transferred to supported nitrocellulose and then
hybridized with the Gal4 binding domain antibody (Santa Cruz Biotechnology).
Each construct was also tested for auto-activation by transforming the plasmid DNA
into AH109 yeast with an empty activation domain vector, plating on SD media
lacking leucine, tryptophan, adenine and histidine and containing α-galactosidase (AHLT αgal) and verifying there was no positive interaction. A positive interaction is
defined as colonies that can grow on –AHLT αgal media and turn blue. Neither
construct grew on selective media when transformed with an empty activation
domain vector.
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Amplification of fetal brain library:

A human fetal brain library consisting of

cDNA from 4-5 fetuses of 20-25 weeks gestational age, was purchased from
CLONTECH. This library contains cDNA fragments of 400 to 4500 bp inserted
into the pACT2 plasmid with EcoRI and XhoI restriction sites in frame with the
GAL4 activation domain (AD). pACT2 has the selection marker –leu for selection in
yeast and is ampicillin resistant for selection in E. coli. The library was amplified to 3
x 106coverage according to manufacturer instructions (Clontech 1999). The
collected amplified library plasmid DNA was purified using the Qiagen Mega-Prep
kit according to manufacturer specifications (Qiagen).
Yeast transformation and screening: Saccharomyces cerevisiae strain AH109 was cultured
in Yeast extract Peptone Dextrose with 0.03% adenine hemisulfate media (YPDA)
until reaching log phase. One microgram of each the bait plasmid and the library
plasmid were co-transformed into the yeast using the LiCL method with the
Yeastmaker™ Yeast Transformation Kit (CLONTECH). Transformed yeast was
collected and then cultured in YPDA for 1-3 hours prior to plating on –LT and –
AHLTα-gal media plates. Plates were then incubated at 30º C for 5 days, and then –
LT plates were counted and co-transformation efficiency was calculated using the
following formula (Clontech 1999):
Count the colonies (cfu) formed on a diluted –LT SD plate
________CFU x total suspension volume (µl)_______ = cfu/µg DNA
Volume plated (µl) x dilution factor x µg library plasmid
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Transformation efficiency is then used to calculate the number of clones screened
using the following formula: cfu/µg x µg of library plasmid used = # of library
clones screened (Clontech 1999). Colonies growing on –AHLTα-gal and turning
blue were selected and re-plated in a grid pattern on –AHLTα-gal plates and
incubated at 30ºC for 5 days with a positive control reference on each plate.
Colonies that grew and were blue on the second plating were considered positive and
were selected for follow-up studies. The selected library plasmids were isolated
using the Zymoprep II yeast plasmid isolation kit (ZymoResearch). Isolated
plasmids were amplified with pACT2 specific primers: F- CTATTCGATGATGAAGATACCCCACCAAACCC and R- GTGAACTTGCGGGGTTTTTCAGTATC with the following PCR conditions: 95ºC for 5 min., 95ºC for 30 sec., 64ºC
for 30 sec., 72ºC for 45 sec. for 30 cycles followed by a 7 min. extension at 72ºC.
Amplicons were purified and then sequenced as previously described. Sequences
were analyzed using BLASTN and BLASTX algorithms from the NCBI website
(http://www.ncbi.nlm.nih.gov/BLAST). Clones containing sequence of only a 3’
UTR were discarded. Isolated clones with sequence matching a coding region of a
gene were selected for further analysis. Yeast plasmid DNA from clones selected
for further analysis was amplified by transforming into competent E. coli and
selecting for ampicillin resistance. Plasmid DNA was purified from bacterial
colonies as previously described. The plasmid DNA was then co-transformed with
the bait vector plasmid DNA into AH109 yeast and plated on –LT and –AHLTα-gal
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media. Clones that were positive for this test were co-transformed into AH109 yeast
with the empty bait vector pGBKT7 and plated on –LT and –AHLT α-gal media.
Clones that grew with the empty vector on –AHLT α-gal were considered false
positives and discarded.
Co-immunoprecipitation Co-immunoprecipitation was performed using the
Matchmaker™ CO-IP kit (CLONTECH). The pACT2 vector does not contain a T7
promoter sequence and this was added to the selected prey plasmids via PCR with
the following primers: F- 5’AAAATTGTAATACGACTCACTATAGGGCGACCCGCCACCATG 3’ and R- 5’ – ACTTGCGGGGTTTTTCAGTATCTACGAT 3’
with PCR conditions as recommended by the manufacturer (Clontech 2006) as
follows: 94ºC for 1 min., followed by 2 cycles of 94ºC for 15sec., 72ºC for 5 min.,
followed by 2 cycles of 94ºC for 15 sec. 70ºC for 5 min., followed by 94ºC for 15
sec., 68ºC for 5 min. for 21 cycles, followed by a 7 min. extension at 68ºC. The bait
plasmid and positive clone prey plasmids were translated using the Promega TnT
Coupled Reticulocyte System (Promega) and 35S-methionine according to
manufacturer instructions. In brief, after the initial T7 translation proteins from the
candidate clones were combined with protein of bait plasmid and incubated with
either the c-Myc or HA antibody and then co-immunoprecipitated with Protein A
beads according to manufacturer instructions (Clontech 2006). This consisted of
adding 10 µl of combined lysate to 3µl of prepared Protein A beads and rotating at
low speed for at least 1 hour at room temperature. After rotating, beads were
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washed six times with manufacturer provided wash solution and then resuspended in
20µl of 0.1% SDS-BPB loading dye. Protein beads were denatured at 95ºC for 5
minutes, electrophoresed on a 15% SDS polyacrylamide gel and then electroblotted
on supported nitrocellulose. Dried nitrocellulose membranes were imaged
radiographically.
Quantitative RT-PCR RNA from transformed human lymphocyte cell lines was
extracted with the RNeasy RNA extraction kit (Qiagen). Samples were further
treated with Turbo DNase-free (Ambion). Primers were designed using Primer Bank
(http://pga.mgh.harvard.edu/primerbank/index.html). The list of primers is
detailed in Table 2.1.
Table 2.1
Primers for Quantitative RT-PCR of AGTR2 Interactors
Primer
Name
ASMTL
ASMTL2
GNB2L1
GAPDH
NGLY1
WDR1

Primer Sequence – 5’ to 3’
F- CAACCGGCTGTACCAGAAAGAC
R- GATCGTGTCCGCTCCAATG
F- CAACCGGCTATACCAGAAAGAC
R- GATCGTGTCCGCTCCAATG
F- GACCATCATCATGTGGAAACTGA
R- CCGTTGTGAGATCCCAGAGG
F- GAAGGTGAAGGTCGGAGTC
R- GAAGATGGTGATGGGATTTC
F- GACTGGCACATGGTATATTTGGC
R- TGCTGTATCAGATCGCAATTTCC
F- GGAGCACCTGTTGAAGTATGAG
R- GAAGAGCCACTATCCCAGAGG

Annealing Temp.
ºC
61
60
60
61
55
55

Quantitative RT-PCR was carried out using I-Script One-Step RT-PCR kit with Sybr
Green (Biorad) in a total volume of 25 µl on the Biorad I-cycler (Biorad). All
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samples were analyzed in triplicate using 5 ng total RNA and analyzed using the
standard curve method (Larionov et al. 2005).
Genomic PCR Human DNA isolated from lymphocytes was amplified as previously
described in Chapter One. The following primers were used: ASMTLex13F- 5’
TCTCCCATCCCTATCCCTAGA 3’ and ASMTLex13R- 5’ TGACGGAGTGTTCAATGGAG 3’. The following PCR conditions were used: 95ºC for 5 min.,
followed by 95ºC for 30 sec., 60ºC for 30 sec., 72ºC for 30 sec. for 30 cycles
followed by a 7 min. 72ºC extension. This produces a 400 bp amplicon. For
densitometry analysis 100ng of each patient sample was used in the PCR. After gel
electrophoresis on a 1.8% agarose gel, samples were analyzed using the densitometry
program of the Alpha-Imager (AlphaInnotech).

Rf values of each sample were

then compared to quantitate gene dosage.
Results
Identification of candidate interacting proteins
Proteins from the C-terminal and N-terminal constructs, the empty bait
vector pGBKT7 and AH109 yeast were isolated and analyzed by Western blot. An
antibody to the Gal4 BD domain was hybridized to the blot and confirmed that
both constructs were producing the expected protein. Western blot analysis showing
the appropriate sizes for each construct is shown in Figure 2.1.
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~23 kDa
17.5 kDa

Figure 2.1– Western blot using Gal4BD antibody of yeast transformed with no
construct (AH109), pGBKT7 with the AGTR2 C-terminal, pGBKT7 with the
AGTR2 N-terminal, and pGBKT7 alone (pGBKT7). AGTR2 constructs are
expected to be ~5kD larger than the empty vector.
The C-terminal intracellular domain of AGTR2 construct was screened
against the human fetal brain library. A total of 2.11 x 106 clones were screened. No
positively interacting clones were identified.
Screenings of the N-terminal extra-cellular domain totaling 944,700 clones
resulted in 376 positive clones. Positive clones were then restreaked on –AHLT αgal plates. Of these, 108 clones were selected for sequencing. Sequences were
analyzed using BLASTN and BLASTX (http://www.ncbi.nlm.nih.gov/BLAST/) to
identify clones with inserts in frame and coded for a protein. Of the 108 clones
sequenced, 39 were selected for further testing as they fit this criteria. Further
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testing included re-interacting the selected prey plasmid with the N-terminal
construct via yeast transformation and also interacting it with the empty pGBKT7
plasmids. Library plasmids that failed to re-interact with N-terminal construct or
interacted with the empty pGBKT7 plasmid were considered false positives. After
this screening, 19 clones remained, representing 7 genes, which are detailed in table
2.2.
Table 2.2
Candidate Gene Results from Screening of AGTR2 N-term
Gene

Gene ID

symbol

Number of

HA Co-IP

clones

C-myc Co-

Protein size

IP

Asmtl

NM_004192

1

yes

yes

15 kd

Aplp1

NM_005166

12

yes

yes

8 kd

Chrom 12p

1

No translation

N/A

N/A

Chrom 1

1

No translation

N/A

N/A

Gnb2L1

NM_006098

2

yes

yes

20 kd

Ngly-1

NM_006098

1

yes

yes

10 kd

Wdr1

NM_017491

1

yes

yes

20 kd

Confirmation of AGTR2 interacting proteins
Clones listed in Table 2.2 were further analyzed by co-immunoprecipitation
after T7 translation. Clones Chrom12p and Chrom1 were eliminated as they failed
to translate. The other five interaction candidates (ASMTL, APLP1, GNB2L1,
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NGLY-1 and WDR1) were found to make a specific protein in a T7 translation
assay. These clones are shown on selective yeast media with positive and negative
controls in Figure 2.2

Positive ctrl
ASMTL/Nterm

Negative ctrl

WDR1/Nter
GNB2L1/C-term
NGLY1/Nter
GNB2L1/Nter

-LT plate

ASMTL/N-term
WDR1/Nter

Positive ctrl

Negative ctrl

NGLY1/Nterm

GNB2L1/C-term

GNB2L1/Nter

-AHLT α-gal plate
Figure 2.2 Positive clones on non selective (-LT) and selective (-AHLT) media.
Positive clones turn blue in the presence of alpha-galactosidase. All clones
containing both AD and BD plasmids grow on –LT media. Only clones with
interacting proteins grow on –AHLTαgal media and turn blue.

65

The positive control consisted of the pVA3-1 (containing the Gal4BD and p53T
antigen) and pTD1-1 (containing the Gal4AD and SV40 large T antigen). This
control grows on –AHLTαgal media and demonstrates strong β-Galactosidase
activity. The negative control consisted of pLAM5’ (containing the Gal4BD and
human β-lamin) and pTD1-1. This control grows on –LT media, but will not grow
on –AHLTαgal media.
Of these clones, three were verified by co-immunoprecipitation (Figures 2.3 and
2.5). APLP1 and WDR1 were also found to co-immunoprecipitate with the
pGBKT7 murine p53 control construct (figure 2.4) and thus were considered false
positives. Co-immunoprecipitation was confirmed using both the c-Myc antibody,
which is specific for the bait plasmid, and the HA antibody, which is specific for the
library prey plasmid. Three proteins, ASTML, GNB2L1 and NGLY1, were
identified as positive interactors.

66

Figure 2.3: CO-IP with c-Myc ab. 1= pGADT7 SV40 and pGBKT7 Murine p53
controls, 2 = APLP1 and ECD, 3 = ECD alone, 4 = NGLY1 and ECD 5 = Asmtl
with ECD, 6 = GNB2L1 and ECD

Figure 2.4 CO-IP of candidate proteins and control with HA antibody. 1 =
pGADT7 SV40 and pGBKT7 Murine p53 controls, 2 = APLP1 and pGBKT7
control, 3 = ASTML and pGBKT7 control 4 = GNB2L1 and pGBKT7 control 5 =
NGLY1 and pGBKT7 control 6 = WDR1 and pGBKT7 control. In lane 2 a band
corresponding to the pGBKT7 control is seen, indicating that APLP1 is a
false=positive.
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Figure 2.5: CO-IP of candidate proteins and AGTR2 N-terminal with HA antibody.
1 = ASMTL and ECD, 2 = GNB2L1 and ECD, 3 = NGLY1 and ECD. The HA
antibody did not give as clean a result as the c-Myc antibody, causing extra bands on
the image.
Evaluation of G21V mutation with candidate AGTR2 interactors
An N-terminal extracellular domain construct containing the G21Vmutation in
the pGBKT7 vector was interacted individually with APLP1, ASMTL, GNB2L1,
NGLY1 and WDR1. This construct interacted with all five of these clones.
Analysis of Candidate Protein Specificity
GNB2L1 has previously been shown to interact with the angiotensin II
receptor-associated protein (Agtrap) which in turn interacts specifically with the
carboxy terminal of AGTR1 (Wang et al. 2002). To test the specificity of
GNB2L1 binding to AGTR2, the positive clone containing GNB2L1 was also cotransformed with the carboxy terminal of AGTR2 both in AH109 yeast and by coimmunoprecipitation. GNB2L1 was found to positively interact with the AGTR2 C-

68

terminal in yeast, (see Figure 2.2) and by co-immunoprecipitation (Figure 2.5, lane 1).
NGLY1 and ASMTL were also found to interact with the C-terminal of AGTR2 via
co-immunoprecipitation. When co-transformed with the C-terminal construct in
AH109 yeast, ASMTL did not interact as strongly with the C-terminal construct as
with N-terminal construct, as indicated by α-galactosidase activity. Ngly-1 was found
to only interact with the N-terminal construct in AH109 yeast as it failed to have any
growth on –AHLTαgal media when co-transformed with the C-terminal construct.

Figure 2.6 CO-IP of AGTR2 C-terminal and positive interactors with c-Myc
antibody. 1 = GNB2L1 and C-term, 2 = NGLY1 and C-term, 3 = ASMTL and Cterm, 4 = C-term alone.
Expression of AGTR2-interactive genes in patients with AGTR2 gene mutations
To examine if the AGTR2 mutations affected the expression of the interacting
partners identified in our study, quantitative RT-PCR was performed using total
RNA from transformed leukocytes. Samples were collected from the patient with no
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AGTR2 expression (CMS0813), her parents (CMS5065 and CMS0814), a patient
with the G21V mutation (CMS5103) and two patients with the FS at F132 mutation
(CMS0690 and CMS4481). Expression of ASTML, GNB2L1 and NGLY1 was
examined. The results are shown in Figures 2.6, 2.7 and 2.8.

NGLY1 Expression

Expression Level

2.50

2.07

2.00
1.50
1.03

1.17

1.00
0.50

1.77

1.66

0.77

0.60

0.47

0.00
0690

0813

0814

4481

5065

5103

ctrl
ctrl male
female

Figure 2.7 Expression of NGLY1 in human transformed lymphocytes. 0690 –
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814
– mother of 0813, 5065 – father of 0813, 5103 – patient with G21V mutation,
control female and control male. Error bars show standard deviation. Expression is
normalized to GAPDH.
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GNB2L1 Expression

Expression Level

3.00
2.39

2.50
2.00
1.50
1.00

0.56

1.01

0.81

0.93

1.04
0.45

0.33

0.50
0.00
0690

0813

0814

4481

5065

5103

ctrl
female

ctrl male

Figure 2.8 Expression of GNB2L1 in human transformed lymphocytes. 0690 –
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814
– mother of 0813, 4481 – patient with 395/402Del T, 5065 – father of 0813, 5103 –
patient with G21V mutation, control female and control male. Error bars show
standard deviation. Expression is normalized to GAPDH.

ASMTL Expression

Expression

1.80
1.60
1.40

1.46
1.22

1.20
1.00
0.80
0.60
0.40
0.20
0.00

1.00

0.85
0.65
0.41
0.01
0690

0813

0814

4481

5065

5103

ctrl female

Figure 2.9 Expression of ASMTL in human transformed lymphocytes. 0690 –
patient with 395/402Del T deletion, 0813 patient with no AGTR2 expression, 0814
– mother of 0813, 5065 – father of 0813, 5103 – patient with G21V mutation and a
control female. Errors bars show standard deviation. Expression is normalized to
GAPDH.
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Quantitative RT-PCR indicated that one patient (CMS0690) with the FS at
F132 mutation had no expression of ASTML. However, the other FS at F 132
mutation patient had expression in the normal range (Figure 2.8). As the ASMTL
gene is in the pseudo-autosomal region of the X and Y chromosome, PCR using
densitometry was used to ascertain whether the patient had two copies of ASMTL.
PCR of genomic DNA with densitometry indicated that patient CMS0690 has an
intact ASMTL gene on both the X and Y chromosomes (data not shown). No
conclusions were drawn regarding the expression of both the NGLY1 and GNB2L1
genes, as there was significant variability between all subjects tested (Figures 2.6 and
2.7).
When the RNA expression of GNB2L1 from brains of Agtr2-/y mouse
embryos was compared with that of normal ones using quantitative RT-PCR,
expression was 1.5 fold lower (p = 0.1) in Agtr2-/y mouse brains (see Chapter One,
page 45). When examining the same expression in P1 Agtr2-/y mice, Gnb2l1 was
slightly higher, but not significantly (p = 0.6). The two microarray probes
representing Gnb2l1 showed a 1.3 and 1.2 fold decrease in expression in the Agtr2-/y
E15 brains, but no significant change at P1. No mouse homologue is currently
known for ASTML. Microarray analysis revealed little difference in expression
between Agtr2-/y brains for Ngly1 at either developmental stage.
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Discussion
This study identified three proteins, GNB2L1, NGLY1 and ASMTL, that
interact with AGTR2. To identify AGTR2 interacting proteins, a human fetal brain
library was used in a yeast two-hybrid screening system. These interactions were
observed in-vivo (yeast 2-hybrid) and in-vitro (co-immunoprecipitation).
The AGTR2 N-terminal extracellular domain interacted with amino acids 119317 of GNB2L1. This domain, which contains almost the entire coding sequence,
consists of exons 2 through 8 of GNB2L1 (Figure 3.12). Quantitative RT-PCR
showed that GNB2L1 is down-regulated in Agtr2-/y E15 mouse brains, but not in P1
Agtr2-/y brains. This may suggest a specific function for AGTR2/GNB2L1 binding
that is unique to the earlier developmental period.
GNB2L1 is a seven bladed beta-propeller protein made of 316 a.a., containing
seven WD40 repeats and acts as an intracellular adaptor protein (Sklan et al. 2006).
The GNB2L1 gene is located at 5q35.3, and consists of eight exons that code for a
cDNA transcript that is 1142bp in length (Wang et al. 2003). It belongs to the family
of receptor for activated protein C (RACK) proteins and also belongs to the family
of WD40 repeat proteins (Wang et al. 2003). It is expressed highly in many tissues,
expressing the same size transcript (Wang et al. 2003).
Both AGTR2 and GNB2L1 are expressed at different levels at different
stages of development in the embryonic and fetal brain, but in the same areas.
GNB2L1 (RACK1) and AGTR2 are first expressed at mouse embryonic day
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11.5(Nuyt et al. 1999; Ashique et al. 2006). GNB2L1 is expressed in a gradient
throughout the developing brain and is highest in the telencephalic areas (Ashique et
al. 2006). AGTR2 is expressed at moderate to low levels in the telechephalon late in
fetal development, but at higher levels in developing brain areas concerned with
motor functions (Nuyt et al. 1999). Western blot comparison of hippocampal lysates
from E13.5, E18.5 and P21 mice probed with anti-RACK1 antibody show a gradual
decrease of RACK1 expression in the hippocampus through development (Ashique
et al. 2006). In postnatal and adult brains both GNB2L1 and AGTR2 are highly
expressed in the cerebellum and both are expressed in the hippocampus(Ashique et
al. 2006; von Bohlen und Halbach and Albrecht 2006). This may indicate a role for
an interaction of AGTR2 and GNB2L1 in the development of the hippocampus. At
the cellular level, GNB2L1 and AGTR2 are expressed in neural cells but not glial
cells (Gendron et al. 2003; Ashique et al. 2006). Together these findings support a
likely role for the interaction of GNB2L1 and AGTR2 in brain development and
function.
GNB2L1 is a scaffolding protein that has many functions including affecting
other scaffolding proteins, cell adhesion, NMDA activation and dopamine transport
(Sklan et al. 2006). NMDA receptors are important to synaptic plasticity, learning
and memory and neuronal development (Dang et al. 2006). GNB2L1 has been
shown to inhibit the function of NMDA receptors by binding Fyn, the substrate for
the NR2B subunit of NMDA receptors (Yaka et al. 2002).
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AGTR2 has previously been shown to have effects on neurite outgrowth and
cell differentiation probably through rearrangements of the cytoskeleton (Gendron et
al. 2003). Recently it has been demonstrated that GNB2L1 binds to human
angiotensin II receptor-associated protein (AGTRAP) which in turn interacts with
the C-terminal of AGTR1 acting as an inhibitor of AGTR1 signaling (Wang et al.
2002). The study described here demonstrated that GNB2L1 interacts with the
AGTR2 receptor at both the C-terminal and N-terminal in yeast 2-hybrid
interactions and co-immunoprecipitation.
AGTR1 and AGTR2 counter-balance the actions of each other physiologically
(von Bohlen und Halbach and Albrecht 2006). AGTR2 has been shown to be a
direct antagonist of AGTR1 in COS-7 and rat fetal fibroblasts (AbdAlla et al. 2001).
It is possible that the GNB2L1 /AGTRAP complex could be a mediating complex
for AGTR2 and AGTR1 in some tissues. Such speculation would require additional
studies.
The AGTR2-interacting protein N-glycanase 1, (NGLY1), is a 654 amino acid
protein that is thought to participate in the degrading of misfolded glycoproteins by
the proteasome (Suzuki et al. 2003). The NGLY1 gene is located on human
chromosome 3p24.2, is 64,226 bp in length consisting of 11 exons. It consists of a
PUB, transglutaminase and PAW domains (Allen et al. 2006).

It is primarily a

cytosolic protein (Park et al. 2001) and is expressed in the heart, brain, liver, kidney
and testis and is highly conserved in eukaryotes (Suzuki et al. 2003). This screening
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found that the amino terminal of AGTR2 interacts with the last 85 amino acids of
NGLY1 in its C-terminal, the PAW domain (Figure 2.9).
Mouse Ngly1 has also been shown to interact with mouse Hr23b, (the mouse
homologue of yeast Rad23p) which links Ngly1 to the proteasome (Park et al. 2001).
The same study also found that mouse Ngly1 interacted with mouse S4, which is a
19s proteasome subunit, and required the N-terminal domain of Ngly1 for the
interaction. The N-terminal domain is a PUB domain that is unique to mammals
(Park et al. 2001; Allen et al. 2006). Park and co-workers (2001) proposed that Ngly1
may recruit proteins interacting with the ubiquitin proteasome and link them to the
26S proteasome for degradation of unfolded glycoproteins. Li and associates
confirmed this hypothesis by finding that Ngly1 forms a complex with p97, Amfr,
mY33K and mHr23b to combine ubiquination and deglycosylation actions that send
misfolded glycoproteins to the proteasome (Li et al. 2005; Li et al. 2006).
AGTR2 is a glycosylated protein whose N-linked oligosaccharide side chains
vary according to the tissue in which it is expressed (Servant et al. 1996). Some
membrane proteins have to be N-glycosylated for cell surface expression (Servant et
al. 1996). While the N-terminal of AGTR2 is necessary for the binding of
angiotensin II (Servant et al. 1997), glycosylation is not necessary for cell surface
expression or angiotensin II binding (Servant et al. 1996). If deglycosylation does
not affect these processes, does NGLY1 bind with AGTR2 as part of the process of
apoptosis through the proteasome? Our microarray analysis of mouse E15 and P1
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brains from Agtr2-/y and control mice (see Chapter 1) found several genes involved
in the ubiquitin/proteasome pathway dysregulated, providing evidence that may
suggest that AGTR2 may also be involved with the proteasome.
ASMTL is a 629 amino acid protein that is not well characterized. This gene
maps to the pseudo-autosomal region Xp22.3 and Yp11.3 (Ried et al. 1998). The
amino terminal of AGTR2 interacted with amino acids 487- 621 the methyltransferase domain of ASMTL (Figure 2.8). This domain catalyzes the reaction of Sadenosyl-L-methionine and N-acetylserotonin to S-adenyl-L-homocysteine and
melatonin. ASMTL is widely expressed in all tissues except adipose or nerve tissue
(UniGene/database). RNA expression of this gene was found to be absent in one
patient with a FS132 mutation in AGTR2, but not in his affected maternal cousin
with the same mutation. Other patients with AGTR2 mutations had expression
within the range of normal controls (Figures 2.8).
Further study is needed to describe the function of the ASMTL gene with
AGTR2. Co-localization studies in cell lines could further illuminate where both
genes interact in the cell. It would be also interesting to investigate whether the
interaction of ASMTL and AGTR2 is unique to the developing brain.
This study did not find any interaction of the AGTR2 C-terminal with the fetal
brain library. While other studies have found this domain to interact with specific
proteins, none of those studies utilized a fetal brain library. Interactions with the Cterminal domain were found in-vitro however, and this may due to co-
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immunoprecipitation being a more sensitive assay than in-vivo yeast 2-hybrid
screening. Even though protein production of the C-terminal construct was verified
by western blot, technical problems cannot be ruled-out.
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Figure 2.10 Graphical representation of the portion of each positive clone that
interacts with the amino terminal of AGTR2. Most of the ORF of GNB2L1 was
present in the prey construct. Only the PAW domain of NGLY1 interacts with
AGTR2 in this study. The methyltransferase domain of ASMTL interacts with
AGTR2.
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With the exception of one patient with no ASMTL expression, no significant
differences were noted in the expression of candidate genes in the AGTR2 mutation
patients. This may be explained by the RNA being collected from leukocytes rather
than brain tissue, or that these protein interactions are only seen during the fetal
period. Mutations in AGTR2 may also have no effect on the expression of these
genes.
In summary, this study has characterized three proteins expressed in fetal brain
that interact with AGTR2. GNB2L1 is a scaffolding protein, highly expressed
throughout brain development and has previously been shown to interact with many
other proteins. Pathway Studio software was utilized to identify targets common to
AGTR2 function. GNB2L1 has many cellular targets in common to both AGTR1
and AGTR2 (Figure 2.10). In particular, GNB2L1 binds PTPN11 (aka SHP-2)
(Kiely et al. 2005) which is down-regulated by AGTR2 (Elbaz et al. 2000) and
AGTR1 (Marrero et al. 1998). SHP-2 has been shown to interact with ATIP after
AGTR2 stimulation, which induces MMS2 expression. MMS2 plays an important
role in neural differentiation (Li et al. 2007). The interaction of AGTR2 and SRC
has also been shown to influence neural differentiation (Li et al. 2007),
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Figure 2.11 Pathway Studio (Ariadne Genomics, Rockville, MD) demonstration of
common targets of AGTR1, AGTR2 and GNB2L1. Pink shapes = proteins, orange
octagons = functional groups, yellow squares = cellular functions, purple lines =
binding, blue lines = expression, gold lines = protein modification, grey lines =
regulation. Direction of arrows indicates up-regulation. Straight line instead of an
arrow indicates inhibition. Small squares on lines are references than can be accessed
via the Pathway Studio program.
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and SRC is shown to be bound by GNB2L1. Also, GNB2L1 and AGTR1 are
involved in the insulin pathway through insulin II (INS) and the insulin growth
factor one receptor (IGF1R). AGTR2 and GNB2L1 are connected in the insulin
pathway through insulin receptor substrate one (IRS1).
NGLY1 cleaves oligosaccharides and participates in the proteasome.
Perhaps it is involved with AGTR2 in apoptosis via the ubiquitin-proteasome
system. ASMTL has an unknown function, but has a methyltransferase domain that
interacts with AGTR2.
As AGTR2 is expressed in different brain areas depending on developmental
stage, it would be interesting to investigate the expression pattern of NGLY-1 and
ASMTL in the developing brain also. These newly identified AGTR2 interactors add
to the complex picture of AGTR2 function in the developing brain.
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CHARACTERIZATION OF THE AGTR2 INTERACTING PROTEIN (ATIP)
Several previous studies have identified different AGTR2 regions responsible
for the interaction with other proteins involved in AGTR2 activation and regulation.
The cytoplasmic intracellular domain of AGTR2 has been shown to contain a
binding domain for ERBB3 (Knowle et al. 2000), PLZF (Senbonmatsu et al. 2003)
and NHE6 (Pulakat et al. 2005). In an effort to better the signaling mechanisms of
AGTR2, Nouet and colleagues (Nouet et al. 2004) identified a novel interacting
protein called the AGTR2 Interacting Protein (ATIP) that interacted with the Cterminus of AGTR2. Subsequently the human homologue was isolated from a
human lung cDNA library and mapped to 8p21.3 (Nouet et al. 2004). Northern
analysis probed with the 354bp cDNA identified as the ATIP interacting domain
(ATIP-ID) revealed a 1.9 kb transcript in all tissues (spleen, thymus, prostate, testis,
ovary, small intestine and colon) tested. It was determined that ATIP had four
transcripts with varying lengths in the N-terminal domain, but all containing the
ATIP-ID and C-terminal domain. Functional studies revealed that the binding of
ATIP to the AGTR2 cytoplasmic tail inhibited cell proliferation (Nouet et al. 2004).
This gene was found to be identical to the already annotated gene Mitochondrial
Suppressor Gene One (MTSG1).
Subsequently, Wruck and co-workers (Wruck et al. 2005) identified the
ATIP mouse homologue, termed ATB50, in a yeast two-hybrid screen with the Cterminus of AGTR2.

The protein had 440 amino acids. These authors found this
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protein and AGTR2 are co-expressed in mouse tissue. In addition, in-situ
hybridization of AGTR2 knockout mouse tissues revealed the expression of
ATBP50 was less than 10% of that of normal animals (Wruck et al. 2005). Studies in
COS-7 cells with fluorescent markers showed that ATBP50 proteins localized to the
golgi matrix. Using siRNA they found that the ATBP50 isoform is necessary for
surface expression of AGTR2.
The Wruck group (2005) also found that the ATBP50 isoform is the result of
alternative splicing, as all three isoforms they identified had exons 7 to 15, but
ATBP50 uniquely contained exon 6. The other two isoforms identified, ATPBP60
and ATPBP135 were not found to be expressed in the brain and spleen nor did they
interact with AGTR2, as ATBP50 did. These authors also found that stimulating
PC12W cells with angiotensin II causes a strong expression of ATBP50 (Wruck et al.
2005).
Di Benedetto and colleagues described the genomic structure and expression
patterns of the human ATIP (Di Benedetto et al. 2006). The ATIP gene spans 112
kb consisting of 17 exons and maps to chromosome 8p21. Five transcripts: ATIP1,
ATIP2, ATIP3a, ATIP3b and ATIP4 were identified. The ATIP1 isoform is the
most predominately expressed isoform in adult brain and is a 436 amino acid
protein. ATIP2 is a 770 amino acid protein found to be expressed at very low
levels in all tissues examined. The isoforms ATIP3a and ATIP3b are large
transcripts and are expressed in many tissues, but at low levels in the adult brain.
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ATIP3a and ATIP3b consist of 1270 and 1216 amino acid proteins respectively.
ATIP4, the only form expressed in fetal brain, is a 517 amino acid protein. It is also
expressed at relatively high levels in the cerebellum in the adult brain. The genomic
structure of each isoform is summarized in Figure 3.1.

Figure 3.1 Exon structure of ATIP isoforms. White boxes indicate exons common
to all transcripts. Black box indicates ATIP1 specific exon. Hatched boxes indicate
Exons used by ATIP3 and/or ATIP 4 transcripts. Note that exon five is unique to
ATIP4. (Figure used by permission from Di Benedetto et al. 2006 figure 1A).
In this study the potential for ATIP to be a causal gene for MR was explored.
The ATIP4 isoform was of particular interest as it is the only isoform expressed in
the fetal brain, having the potential to interact with AGTR2 and affect brain
development. Brain expression was elucidated through the use of Northern blots of
sections of adult brain. A mutation screening of ATIP in patients with MR was also
undertaken.
The seventeen exons of ATIP were analyzed in 80 patients. Particular
attention was given to the screening of exon 5 because of its unique expression in

85

fetal brain. Exon 5 was screened in 500 patients with MR. We found no significant
mutations in any of the patients screened.
Methods
Northern blots and probes The ATIP-ID 354 bp probe was made by amplifying
human cDNA with the following primers: F- 5’ CAGGCTGAAAAAACAGAACGA 3’and R- 5’ TTTTTCATTTAAAGCATCATT 3’. PCR conditions
were as follows: Denaturation at 95ºC for 5min. then 95ºC for 30 sec., 55ºC for 30
sec., 72ºC for 30 sec. for 30 cycles followed by a 7 min. extension at 72ºC. The 354
bp 32P labeled product was hybridized to Northern blots containing poly A+ RNAs
from different human brain sections (from individuals of ages 16-75 years)
(Clontech) using ExpressHybe (Clontech) at 65ºC for 1 hour after pre-hybridizing at
65ºC for 2 hours. The filters were washed with of 2X SSC-0.05% SDS solution at
65ºC for 40 minutes and then with 0.1X SSC-0.1% SDS solution at room
temperature for 20 minutes. The filters were exposed to Biomax film (Kodak) 24
hours and for 5 days at -80ºC.
Mutation screening Mutation analysis was performed using Denaturing High
Pressure Liquid Chromatography (DHPLC) or Incorporation-PCR Single-Strand
Conformation Polymorphism (IPS). Amplicons were amplified with the primers
listed in Table 3.1 (primer sequences were provided by Dr. C. Nahmias) by using 1
ng of genomic DNA with 1X PCR buffer, 125 µM dNTPS, 1 µCi of αP33 dCTP
(3,000Ci/mmol), 0.5 µM of each primer and 1U of GO Taq™ polymerase
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(Promega) in a 10µl reaction. PCR conditions were as follows: 95ºC for 5 min.
followed by 95ºC for 30 sec., appropriate annealing temperature for 30 sec., 72ºC for
30 sec. for 30 cycles followed by a 7 minute extension at 72ºC. Ten microliters of
formamide/NaOH BPB buffer was added to each sample and then they were
denatured at 95ºC for 5’ and placed on ice. Samples were loaded on a 6% MDE gel
(FMC) and run at constant power of 8W from 16-20 hours. Gels were dried and
visualized with X-Ray Biomax film (Kodak) at room temperature. Samples that
demonstrated a banding pattern or shift that differed from normal controls were
selected for sequence analysis.
Amplicons selected for DHPLC were amplified using 20 ng of human
genomic DNA, 1X PCR buffer, 250µM dNTPs, 1.0 µM of each primer and 1U of
GO Taq™ polymerase (Promega) in a 20 µl reaction. Five µl of each PCR mix was
run on a 1.8% agarose gel to verify the amplicon. Samples were then pooled in
groups of four. Pooled samples were heteroduplexed by heating to 94ºC for seven
minutes and then 55ºC for four minutes. DHPLC conditions based on the melting
temperature of each amplicon were selected using the Wavemaker program
(Transgenomics). Chromatography using the appropriate temperatures was
performed and their denaturing profiles were inspected visually.
Samples that showed a profile differing from normal controls were selected for
further analysis. The four individuals from the abnormal pooled sample were PCR
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amplified and then subjected separately to DHPLC analysis. The individual sample
that differed from the normal control was selected for sequence analysis.
Samples selected for sequencing from either IPS or DHPLC were amplified
by using 100 ng DNA genomic DNA, 1 X PCR buffer, 0.5 µM of dNTPs, 1.0 µM
of each primer and 2U of GO Taq™ polymerase in a 50 µl reaction. PCR products
were purified and both strands were sequenced using the DYEnamic ET Dye
Terminator Cycle Sequencing Kit (GE Healthcare) and the automated MegaBACE
1000 DNA analysis system (GE Healthcare). Sequences were analyzed using the
DNASTAR program (Madison, WI USA).
Table 3.1
Primers for ATIP Gene Screening
Exon
Exon 1.1
Exon 1.2
Exon 1.3
Exon 1.4
Exon 1.5
Exon 1.6
Exon 2

Primer sequence 5’ – 3’
F: GACAGACCATTTTGCCCACCCTCTC
R : CAACTGTGTTGCAGATATTTGGGC
F : GTAAGCAGGTGTTAGATATGC
R : GGCTTCTGATGGTGTGACTTGAGG
F : CATCTTCCCATTCTGATAAGACGC
R : CATCAATAAGACAATAGGAC
F : GCTCATACAGGCACAAGGAAATGG
R : GTCTGGTATGTTTTTAAGCCCTCG
F : GTTTCACCGATTGAAGCGACGG
R : GAATGAGTTGTAACATGCACAGCC
F : TAACAAGACACATAAGCAGCAG
R : GCTAACACATCTCAGTTTTCTCC
F : GGGGCCCATTCAGTCAGTTG
R : GACCTATAATCATGACTGTCC

annealing temperature
product size (bp)
ºC
64

444

55

443

55

417

55

413

64

458

55

446

55

356
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Table 3.1 (continued)
Exon 3
Exon 4
Exon 5
Exon 6
Exon 7
Exon 8
Exon 9
Exon 10
Exon 11
Exon 12
Exon 13
Exon 14
Exon 15
Exon 16
Exon 17

F: GATAGCCTATTGTCCTAATGG
R: GCAAGAGAGCAGAAATGATGAGGC
F : CTTAAAAAGTGCCAGCTTTCGGG
R : CATTAGTTTTTCTTGTAATGACTG
F : CATGTTGACTTGGCCACCGTTTC
R : AAATTTAAGCATGCTTACAAAG
F : GGACAAAGGAATAAATGTGG
R : CAAGCCAAGGACTTTAAGCG
F :CCGGGAACCTGAAATGTAGCG
R : GGAAATTCTACTTATAAGCACACC
F : GAGACCACCCACTTTCTCCTCCCC
R : GCAAATTAATGAAGACATCCCCC
F: GTTTTTGAATCCTTGTGGTGG
R: GCGTGTGAGCAAGTCCTCCCCG
F : GCCTAAATGATTCATATCTTGGC
R : AACAGCTCCCAGCATGCAACTCC
F : GTATGCTTCAGGTGTCATCACAGC
R :CCTATTAGACTAAAAAAGAGAAGCTC
F : GCCTTTAAACTAGAGCCCACGC
R : CCACAGGGCATTCGCTGAAGCAGG
F : GGCTTCATCATCAACCCC
R : CGTACACAGAAACATTAAAACC
F : CGTATGCTGAGTTTCTGGGGTT
R : TGTTATTTCTCTGGCTGCTG
F : CGCTTGCTACTTGTCTAATGTC
R : ATAAATATGGAACAAACTTGGA
F : TTTTTCAGTATGTTTGTTAGTGT
R : GCAGGGGTAGAGCGTGTCCAGA
F : GCCAAATACCTGTGACCTTGTGC
R : CCCACGTTCCTCCTTGGGG

55

224

55

290

53

585

55

269

62

267

57+DMSO

539

56

364

56

298

57

408

59+DMSO

336

57+DMSO

259

59+DMSO

248

56

387

57

340

60

438

Characterization of a heterozygous deletion Sequencing of both DNA strands of a
patient with an alternatively migrating fragment of exon 14 produced very poor
sequence results. This was thought to be due to a deletion. To confirm the deletion,
sequencing of both strands was undertaken. To separate the leading and lagging
strands, the exon 14 amplicon was subcloned into the pCR2.1 vector in the TA
Cloning Kit (Invitrogen) as described in Chapter 2. Ten clones containing inserts
were selected and DNA was prepared. Purified plasmid DNA from these clones was
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sequenced as described previously using the following primers: M13F 5’
CTGGCCGTCG-TTTTAC 3’ and M13R 5’ GTCATAGCTGTTTCCTG 3’.
Sequences were analyzed with DNASTAR (Madison WI, USA). This technique
allows for clean sequencing by separating the leading and lagging strands.
Mutation screen via restriction enzyme digest To screen for a possible polymorphic
variant in exon 14, 120 normal controls and the patient with a 4 bp intronic deletion
were amplified with exon 14 primers in a 25 µl PCR reaction as previously described.
Ten microliters of the 238 bp product were then digested with 2 U of Hpa I
restriction endonuclease (New England Biolabs) and 1 X buffer in a 20 µl reaction
and incubated at 37ºC for at least 4 hours. The digest was run on a 3% NuSieve
agarose gel and visualized with ethidium bromide on a UV illuminator. The deletion
destroys the Hpa I site and thus a deletion has a 238 bp band instead of 219bp and
19 bp band. Heterozygotes would have a 238 bp, 219bp and 19 bp bands.
Results
Expression of the ATIP gene in brain
Expression of ATIP has been shown in human brain (Di Benedetto et al.
2006). To monitor the expression pattern in brain regions in humans, a Northern
blot containing RNAs from the different regions of the adult human brain was used.
A cDNA probe containing the ATIP-ID coding region was hybridized to human
adult brain Northern blots (Clontech). The ATIP-ID was found to be expressed in
all brain tissues. A transcript of 4.4 kb was found in all tissues examined. A
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relatively weakly expressed transcript of 7.4 kb was also seen (Figure 3.1).
Expression appeared to be highest in the corpus callosum, cerebellum and thalamus
(Figure 3.1).
PCR of a human fetal brain library with ATIP-ID primers found that this
domain was not expressed in the library made from 20-25 week human fetal brain.
However, the unique transcript, containing exon 5, was expressed (data not shown).
Mutation screening and detection of nucleotide variants in the ATIP gene
The ATIP gene contains 17 exons. All exons were screened in female
patients with MR. These patients previously tested negative for the MR causing
FMR1 gene expansion. Two normal controls and 80 or 160 patients were screened
using either IPS or dHPLC (Table 3.2). Patients with alternatively migrating
fragments were selected for sequencing. Six patients were found to have a
c.1791A>C (p.K435T) alteration in exon one. This alteration was also found in 8 of
90 normal male controls. One patient carried a heterozygous deletion of five
nucleotides (ivs13-22del5). Subsequently, this patient was found to have San Fillipo
syndrome through biochemical testing and thus this deletion is unlikely to be MR
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Figure 3.2 Expression of ATIP isoform in the human brain. Northern blots
(Clontech) containing RNA from different human adult brain sections were
hybridized with a 354 bp ATIP cDNA probe.
causing in this patient. This patient’s deletion was elucidated by subcloning the
exon 14 amplicon and then sequencing a number of insert-containing plasmids. By
this technique the leading and lagging strands were separated and single-strand
sequencing was accomplished. The sequence chromatogram of this patient’s normal
and deleted exon 14 are shown in Figure 3.3. A summary of the mutation screening
is detailed in Table 3.2.
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Figure 3.3 Electropherogram of aligned exon 14 from patient with a 5 bp deletion.
The normal strand is on the top row, the deleted strand in on the second row and
the ATIP exon 14 sequence is on the lower row.
Table 3.2
Mutation Screen Summary for ATIP

Exon

Number
of
Patients
Screened

Nucleotide
Change

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

80
80
80
80
160
160
160
160
80
80
80
80
80
80
80
80
80

c.1791A>C
none
none
none
none
none
none
none
none
none
none
none
none
IVS13-22del5
none
none
none

Amino
Acid
Change
p.K453T

No

Number
of
Patients
with a
shift
6
0
7*
0
0
0
1*
0
0
2*
1*
0
1*
1
0
0
0

*No nucleotide changes were found in these samples.

Number
of
controls
with a
change
8 of 90

0 of 120

Screening
Method
DHPLC
DHPLC
IPS
IPS
DHPLC
DHPLC
DHPLC
IPS
DHPLC
IPS
IPS
IPS
IPS
IPS
IPS
DHPLC
DHPLC
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Discussion
Northern blots of adult brain tissues probed with the ATIP-ID cDNA found
a 4.4 kb transcript and a weakly expressed 7.4 kb transcript. Expression was
comparatively higher in the corpus callosum, cerebellum and thalamus. Expression
was noticeably absent from the spinal cord. No expression of the ATIP-ID was
detected in the human fetal brain library. However, the fetal brain library did
contain cDNA from exon 5, which is specific to the fetal brain isoform of ATIP.
No significant alterations in an initial screen of our MR population were found.
Interestingly, the Atip gene was not found to be dysregulated at either
developmental stage in Agtr2-/y mice. Microarray analysis of Agtr2-/y mice (see
Chapter One) revealed no significant difference in the expression of Atip (alias
Mtus1) from normal controls.
The initial discovery of ATIP was found through a yeast 2-hybrid screen
using the last 52 amino acids of AGTR2 as bait against a mouse fetal cDNA library.
The cDNA region that encoded the 118 amino acids found to interact with AGTR2
was designated the ATIP-ID
The ATIP4 isoform containing exon 5 is the only isoform of ATIP found to
be expressed in fetal brain. This isoform is also expressed in the adult brain,
predominately in the cerebellum, but is not found in any other tissues (Di Benedetto
et al. 2006). Previous analysis of the same adult brain blots used in this study with
AGTR2 cDNA as a probe, found expression only in the cerebellum (Vervoort et al.
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2002).

This is also consistent with the high expression of the ATIP-ID found in

the cerebellum on this study’s northern blots (Figure 3.1). It might be possible that
the interaction of ATIP and AGTR2 is limited to the cerebellum.
Using the C-terminal of mouse Agtr2, Wruck and colleagues, ( 2005) found a
full-length cDNA designated ATBP50, a gene analogous to human ATIP. ATBP60
and ATBP135 were two other ATB isoforms and were found not to interact with
AGTR2. While all three isoforms contained exons 7 to 15, Atbp50 uniquely included
exon six, which is analogous to human ATIP exon eight. Di Benedetto and coworkers discovered that ATIP exon 5 (isoform ATIP4) has a 90% homology to
ATBP60 and ATIP1 unique exon 8 has an 87% homology to ATBP50 (Di
Benedetto et al. 2006). It is interesting to note that the only described mouse
isoform able to interact with AGTR2, ATBP50, is analogous to adult brain ATIP1.
The mouse isoform analogous to fetal brain expressed ATIP4 (ATBP60), was not
shown to interact with AGTR2 (Wruck et al. 2005).
Co-expression of Atbp and Agtr2 in tissues of Agtr2-/y mice was examined by
Wruck and colleagues (Wruck et al. 2005) via is-situ hybridization and quantitative
RT-PCR. Using a probe common to all three isoforms, they examined coexpression of Atbp and Agtr2 in adrenals, kidney, lung, heart and brain from adult
control and Agtr2-/y mice. They found expression patterns of both genes to be
similar in all tissues examined. Using uterine tissue from control and Agtr2-/y animals,
they also found that the expression of Atbp was less than 10% of normal in Agtr2-/y
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mice. The microarray results seen in our study were from brains of control and
Agtr2-/y E15 and P1 mice and no difference was seen between the two groups. This
may be explained by the ATBP50 isoform not being expressed in fetal brain.
The mutation screen of the patient cohort analyzed in this study did not find
any disease causing mutations. ATIP exon 5 specific to the isoform expressed in
fetal brain, was screened for a larger cohort of 500 patients with MR. Mental
retardation is a heterogeneous disorder that is likely caused by many factors.
Mutations in causal genes of MR are rare and are often found at a low frequency.
Thus a larger number of patient samples would need to be screened before ruling
out ATIP as a gene involved in MR. Further investigation of the function of the
ATIP isoform specific to fetal brain may also be pursued to further clarify its role in
developing brain.
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CONCLUSIONS
The functions of AGTR2, a receptor for angiotensin II, are still not fully
understood. While better characterized for its role in blood pressure regulation and
fluid homeostasis, the brain functions of AGTR2 are just beginning to be explored.
The fact that AGTR2 is expressed at higher levels, and in different areas, in the fetal
brain as compared to the adult brain, point to its function in brain development.
The purpose of this study was to further elucidate the function of AGTR2 in the
developing brain.
In Chapter One we explored the differences in gene expression between E15
and P1 Agtr2-/y and control mouse brains. Abnormal dendritic spine morphology
and cell number had previously been observed in Agtr2-/y mice. RNA from eight
knockout and six control E15 brain samples was hybridized to 16 Agilent Whole
Mouse Genome 44K arrays. Data from these arrays was used to produce a list of 52
up-regulated and 10 down-regulated genes in E15 Agtr2-/y mouse brains. RNA from
four Agtr2-/y and four control P1 brain samples were also hybridized to eight arrays.
Data from this experiment produced a final list of 50 up-regulated and 12 downregulated genes in P1 Agtr2-/y mouse brains. Results were verified via quantitative
RT-PCR.
The gene expression profiling analysis in the study revealed a number of
genes involved in microtubule regulation, protein binding, cell adhesion,
transcription, DNA binding and kinases up-regulated in developing brain.
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Transferases, as well as a large number of transcription factors, were up-regulated in
E15 Agtr2-/y mouse brains. Unique to the P1 Agtr2-/y mouse brains were genes
involved in glutamate metabolism, cell cycle control and RNA metabolism. Our
findings add strength to the hypothesis that AGTR2 contributes to the developing
brain by influencing cell morphology and synaptic connectivity.
In Chapter 2, three AGTR2 interacting proteins, GNB2L1, NGLY1 and
ASMTL were identified. These proteins were found by screening a human fetal
brain library with the N-terminal domain of AGTR2. These interactors were also
verified by co-immunoprecipitation. A weak interaction was also noted for
GNB2L1 and ASMTL with the C-terminal of AGTR2. The interaction of NGLY1
was specific to the N-terminal of AGTR2. GNB2L1 is a scaffolding protein with
many functions, and has been shown to be involved in the signaling cascade in the
central nervous system. GNB2L1 may interact with AGTR2 as part of a gene
network that contributes to neuronal differentiation. ASMTL gene function is
largely unknown. NGLY1 participates in degradation of misfolded glycoproteins by
the proteasome. A role for AGTR2 in apoptosis has been described. We
hypothesize that NGLY1 in association with AGTR2 may be involved in apoptosis
through the ubiquitin-proteasome.
In Chapter 3, a partial characterization of a previously identified AGTR2
interacting protein, ATIP, has been discussed. This gene was explored as a potential
MR candidate gene as it has been shown previously to interact with AGTR2 and is
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expressed in the brain. Northern blot analysis of adult human brain tissue found
that the region encoding the ATIP interacting domain (ATIP-ID) is expressed in all
brain tissues. The expression of the Atip gene was not dysregulated at either
developmental stage of the Agtr2-/y mice, possibly indicating that the interaction of
the ATIP isoform with AGTR2 is likely not to be crucial to brain development.
Furthermore, in a human mutation screening we did not identify any MR
disease causing mutations in 80 patients analyzed. Further investigation of the
function of brain specific isoforms of ATIP my further clarify its role in brain
function.
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Mapping of X;7 Translocation in a Female Patient with MR and No AGTR2
Expression
Introduction
A female patient with moderate to severe mental retardation (IQ 44) was
previously found to have a de novo t(X;7)(q24;q22) translocation. The patient has
totally skewed X inactivation in favor of the translocated X chromosome, as
compared to random X-inactivation in her mother with two normal copies of the X
chromosome. Because causative genes are present at long distances in several
disease-associated balanced translocations, expression studies of candidate genes for
the X breakpoint region were performed. This revealed that this patient had no
expression of AGTR2. A subsequent screening of affected males from 33 families
with possible X-linked mental retardation and 552 unrelated males with mental
retardation found nine patients with mutations in AGTR2 (Vervoort et al. 2002).
The X breakpoint region was mapped 150 kb proximal to the AGTR2 gene. The
AGTR2 gene was found not to be disrupted. It was hypothesized that the loss of
expression in the patient with the t(X;7) may result from separation of distant
regulatory elements. Through Fluorescent In-Situ Hybridization (FISH), pulsed-field
and southern blot analysis and Comparative Genomic Hybridization (CGH) it was
determined that the X breakpoint was in a region of a pseudogene near the DXZ4
locus (Vervoort et al., unpublished work). The CUTL1 gene was putatively
disrupted on chromosome 7, but it was determined that the patient had expression

102

of this gene from her normal chromosome 7. In this study the Xq24 and the 7q22
breakpoint were partially mapped.
Materials and Methods
Florescent-InSitu Hybridization (FISH) Lymphocytes from patients were
transformed with EBV and cultured until confluent. BAC clones were selected by
searching the breakpoint region using the NCBI MapViewer
(http://www.ncbi.nlm.nih.gov/mapview/). BAC clones purchased from Chori or
Invitrogen were grown on LB media with chloramphenicol as described in previous
studies. Individual colonies were cultured in LB media with chloramphenicol and
the plasmid DNA isolated using Qiagen Mini-Prep columns as previously described
in Chapter 2. DNA was labeled by incorporation of digoxigenin-11-dUTP
(Boehringer Mannheim) by nick translation using DNA polymerase I (Life
Technologies). Metaphase chromosome spreads were obtained from harvested
patient lymphoblast cell lines and FISH was performed using standard methods
(Vervoort et al. 2002). The labeled probes were visualized with rhodamine-labeled
anti-digoxigenin and the chromosomes were counterstained with DAPI. Images
were examined under a Zeiss Axiphot fluorescent microscope.
Pulsed-Field and Southern Blot Hybridization (Pulsed-field gel Southern blots
were made by V. Vervoort). Total genomic DNA (100ng) was digested with EcoRI
(New England Biolabs) and electrophoresed on a 0.8% agarose gel. The gel was
denatured and transferred to a Hybond (GE Healthcare) charged nylon membrane
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using alkaline 3M NaCL 0.4M NaOH transfer method. After transfer was complete,
membrane was baked at 65ºC for one hour and pre-hybridized with hybridization
solution (4x SSPE, 2X Denhardt’s solution, 0.5% SDS, 6% polyethyleneglycol, 40
mg/ml denatured salmon sperm DNA) at 65ºC for at least 2 hours. Fresh
hybridization solution was then added. DNA probes were labeled with 32P d-CTP
using the Redi-Prime Random Labeling kit (Invitrogen) according to manufacturer
instructions, and then hybridized overnight at 65ºC. Filters were then washed with
5X SSC 0.1% SDS for one min. at 65ºC, 2X SSC 0.1% SDS for 15 min. at 65º C
and then for 15 min. at room temperature; and with 1X SSC, 0.1% SDS for 15 min.
at room temperature. Filters were exposed to Biomax (Kodak) film at -80ºC for at
least 24 hours. Primers used for amplifying specific probes are listed in Table A.1.
(Primers designed by V. Vervoort)
Table A.1
Primer sequences for Probes
Name
Probe 7
Probe 8
Probe 8B
Probe
DXZ4

Sequence
5’ to 3’
F-CTCTCACCTGGTCCCCTTATCTCT
R-GTATGGCCCTGTGGTGGTGTG
F-TTTCCCCATCCCATCTCCACTTGA
R-ATCGCTGCCGCCTCCTTCTTCTG
F-CCTCCCCCAACTCTCCCCTTAGC
R-CTCATATCCGGGACTTGCTGCTCT
F-ACCGGCAAGGGGCTGGGGGAAGAG
R-TGAAGGCGCACGTGGGCAAGAAGT

Annealing Size
Temp. ºC (bp)
68
1171
62

657

55

715

68

2334

Comparative Genomic Hybridization Analysis CGH was carried out using an
Agilent 44K Human Genome Chip (Agilent). Patient and control DNA were first
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quantified to be of equal concentration and then digested with RsaI, labeled with
either dUTP Cy5 or dUTP Cy3 (Perkin Elmer) and hybridized according to
manufacturer protocol. In brief, each CGH slide was hybridized with two DNA
samples: a control and the patient. The control was labeled with either dUTP Cy5 or
dUTP Cy3 and the patient is labeled with the other. Another slide was also used
utilizing a dye-swap strategy. The labeled samples were combined with manufacturer
provided hybridization solution, spread on the CGH slide, sandwiched with a gasket
slide and hybridized in a 65ºC oven with rotation for 17 hours. Slide assemblies
were then unassembled, washed briefly in SSC washes (Agilent part number 51885221 and part number 5188-5222), washed briefly in acetonitrile and also in
proprietary ozone scavenging solution (Agilent part number 5185-5979). Slides were
read on a GenePix 4000B scanner and data was extracted and normalized using
Feature Extraction 8.0 software (Agilent). Analysis of results was performed using
CGH Analytics software (Agilent).
RNA Extraction RNA was extracted from EBV transformed leukocytes using the
Qiagen RNeasy kit (Qiagen) according to manufacturer instructions. Samples were
then DNased using the Ambion Turbo DNase-free kit (Ambion Inc.). Samples were
analyzed on the Agilent 2100 expert bioanalyzer (Agilent) for purity and
concentration as described in Chapter 1.
Quantitative RT-PCR Primers were designed using the Primer3 program from
MIT (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen and

105

Skaletsky 2000). Biorad I-Script 1 step RT-PCR with SYBR green (Biorad) was used
according to manufacturer instructions with 5 ng of RNA per sample used. Samples
were run in triplicate on a Biorad i-cycler and analyzed using a standard curve
method (Larionov et al. 2005)using GAPDH as a control as described in Chapter
One. The primers for RT-PCR are listed in Table A.2.
Table A.2
Primers for Quantitative RT-PCR of CUTL1
Name

Primer Sequence

Cutl1
GAPDH

Annealing Product
Temp. ºC Size (bp)
F-CGGCAGAGGAAGTACCTGAG
60
233 bp
R-TTCTCGTGGAACTTGTGCAG
F-GAAGGTGAAGGTCGGAGTC
61
225 bp
R-GAAGATGGTGATGGGATTTC

Results
Comparative Genomic Hybridization (CGH) is a technique that allows for
scanning an individual’s whole genome at one time in order to find significant
changes in gene dosage. To look for a possible small deletion on either
chromosome 7 or X of patient CMS0813 with the (tX;7), an Agilent 44K Human
genome chip (Agilent) was utilized. This chip has an average probe spatial resolution
of 35 kb. No deletions or duplications were found.
Using FISH probes, the 7q22 breakpoint on the patient’s translocated
chromosome was narrowed to the CUTL1 gene (Figure A.1). This was
accomplished by using probes in succession from the distal (area below the
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breakpoint in the direction of the telomere) and from the proximal (area above the
breakpoint in the direction of the centromere) ends of the breakpoint region until a
probe is found that spans the breakpoint region. A schematic map of the probes for
the breakpoint region is shown in Figure A.1.

Figure A. 1 Map of FISH clones of 7q22 relative the CUTL1 gene on the
translocated chromosome 7 of patient CMS0813. The critical breakpoint region is
located in the intronic region of the CUTL1 gene.
Since the CUTL1 gene appeared to be disrupted on the translocated chromosome 7
of patient CMS0813, a cDNA probe of CUTL1 was hybridized to the
EcoRI/EcoRV pulse-field blot to look for major shifts, but none were found. This
complemented the FISH data as the position of the FISH clones indicated that
majority of the CUTL1 coding region was distal to the breakpoint.
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To further assess whether the patient’s CUTL1 gene was affected by the
breakpoint, quantitative RT- PCR analysis of the patient’s and parents RNA was
performed. This analysis showed the patient had expression of CUTL1 (Figure A.2).
Expression was too variable among all samples analyzed including controls to
accurately assess if the level of patient CMS0813’s expression was affected by the
disruption of CUTL1.

Figure A.2 Quantitative RT-PCR of CUTL1. CMS0690 = patient with truncated
AGTR2 receptor, CMS0813 = patient with no functioning AGTR2, CMS0814 =
control female, CMS5065 = control male, CMS5103 = patient with G21V mutation
of AGTR2. All data normalized to GAPDH. Error bars indicate standard deviation.
A pulse field gel of the digested EcoR1 and EcoRV digest DNA of the
translocation patient, her parents and controls was created in our laboratory
previously. This blot was successively analyzed with several probes derived from
the Xq breakpoint region. This analysis revealed a deleted and shifted region in the
patient’s chromosome X breakpoint area (Vervoort et. al., unpublished data). A
probe made from microsatellite DXZ4 was found to be intact (Figure A.3), as well as
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intronic probe number 7 (data not shown). Probe number 8, a 657 bp region
upstream from DXZ4, was found to be deleted in the patient in both the EcoR1 and
EcoRV digest, as the patient had only her mother’s allele (Figure A..4) Probe
number 8B was found to be shifted in the EcoR1 digest with the patient having her
mother’s allele but missing her father’s allele (Figure A.5).

Figure A.3 EcoRI and EcoRV digest pulse-field blot with probe DXZ4. Males have
one band, females have two bands. Breakpoint patient CMS0813 has one allele from
each parent with both digests indicating her DXZ4 region is intact.
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Figure A.4 EcoRI and EcoRV digest pulse-field blot with probe 8. This probe,
proximal to probe DXZ4, patient CMS0813 has only her mother’s allele, indicating a
deletion of her father’s allele.

Figure A.5 EcoRI and EcoRV digest pulse-field blot with probe 8B. This probe,
proximal to DXZ4 and distal to probe8, shows patient CMS0813 missing her father’s
allele in the EcoRV digest, but shows a lower, shifted band in the EcoRI digest
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A map summarizing the position of these probes and their results can be seen in
Figure A.6.

Figure A.6 Map of X breakpoint region for patient CMS0813. E’s in diamonds
represent Eco RI cut sites. Orange probe 8 is deleted and yellow probe 8B detected
an alternatively migrating fragment.
Southern blot analysis was performed to better elucidate the size of the
shifted fragment in patient CMS0813 seen with probe 8B on the pulse-field gel
electrophoresis blot. The Southern blot analysis showed an approximately 10 kb
band unique to the patient (Figure A.7).
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Figure A.7 EcoRI Southern blot with probe 8B, showing 10 kb band unique to
CMS0813. No bands were expected to be seen in the parental lanes. Further
Southern blot analysis had narrowed the deleted region on the X chromosome in
patient CMS 0813 to the 3 kb region between probe 8 and probe 8B (data not
shown).
Sequence analysis of the probe 8 sequence with BLAST revealed this probe
contained nucleotides 59 to 715 of a predicted gene, LOC728825 (XM_01128769), a
pseudogene homologue of SUMO2 located on chromosome 17q25.1. Some
pseudogenes have been shown to produce active transcripts (Harrison et al. 2005).
The cDNA of CMS0813, her parents and cDNA from a human fetal brain library
was amplified using the probe 8 primers. All of the cDNA produced a 657 bp
product and the genomic DNA produced a 657 bp and 700 bp band (figure A.8).
This second band was produced on several attempts whether the DNA used was
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from a male or female. It is most likely due to the primers amplifying both the
SUMO2 gene and its pseudogene LOC728825. However, the sequence homology
between this pseudogene and SUMO2 is too similar to determine if the pseudogene
produced the transcript.

Figure A.8 cDNA PCR products of probe 8 primer. 1 – 100 bp ladder, 2 –
CMS0813, 3 – CMS0814 (mother), 4 – CMS5065 (father), 5 – fetal brain library, 6 –
genomic DNA from CMS5065 7 – water lane. The genomic samples produced two
bands, likely from the amplification of the SUMO2 gene and the pseudogene.
Previous works have demonstrated that breakpoints substantial distances
from disease causing genes can affect the expression of the primary gene (Pfeifer et
al. 1999; Crisponi et al. 2001). This may also be the case in patient CMS0813. It
remains to be seen if the deleted pseudogene or a genomic element deleted in the
patient may act as a transcriptional regulator for AGTR2.
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In conclusion, we were able to determine that the 7q22 breakpoint maps to
the CUTL1 gene. Furthermore, the Xq24 breakpoint was narrowed to a 3 kb region
that contains a pseudogene.
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